US20090181919A1 - Method for Freeze-Drying Nucleic Acid/Block Copolymer/Cationic Surfactant Complexes - Google Patents
Method for Freeze-Drying Nucleic Acid/Block Copolymer/Cationic Surfactant Complexes Download PDFInfo
- Publication number
- US20090181919A1 US20090181919A1 US12/407,653 US40765309A US2009181919A1 US 20090181919 A1 US20090181919 A1 US 20090181919A1 US 40765309 A US40765309 A US 40765309A US 2009181919 A1 US2009181919 A1 US 2009181919A1
- Authority
- US
- United States
- Prior art keywords
- block copolymer
- cationic surfactant
- formulation
- crl
- cloud point
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001400 block copolymer Polymers 0.000 title claims abstract description 123
- 239000003093 cationic surfactant Substances 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims description 47
- 238000004108 freeze drying Methods 0.000 title abstract description 46
- 102000039446 nucleic acids Human genes 0.000 title description 7
- 108020004707 nucleic acids Proteins 0.000 title description 7
- 150000007523 nucleic acids Chemical class 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 123
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 74
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 74
- 239000004067 bulking agent Substances 0.000 claims abstract description 54
- 239000002577 cryoprotective agent Substances 0.000 claims abstract description 49
- 239000002157 polynucleotide Substances 0.000 claims abstract description 49
- -1 polyoxyethylene Polymers 0.000 claims description 42
- 238000001914 filtration Methods 0.000 claims description 28
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 21
- 229920001451 polypropylene glycol Polymers 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 abstract description 80
- 239000011859 microparticle Substances 0.000 abstract description 23
- 230000002776 aggregation Effects 0.000 abstract description 5
- 238000004220 aggregation Methods 0.000 abstract description 5
- 230000004927 fusion Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 58
- 108020004414 DNA Proteins 0.000 description 45
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 42
- 229930006000 Sucrose Natural products 0.000 description 42
- 239000005720 sucrose Substances 0.000 description 42
- 239000002245 particle Substances 0.000 description 40
- 229960000686 benzalkonium chloride Drugs 0.000 description 37
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 37
- 229910000162 sodium phosphate Inorganic materials 0.000 description 32
- 239000013612 plasmid Substances 0.000 description 29
- 239000001488 sodium phosphate Substances 0.000 description 26
- 235000011008 sodium phosphates Nutrition 0.000 description 26
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 26
- 239000006179 pH buffering agent Substances 0.000 description 24
- 125000002091 cationic group Chemical group 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 229920001983 poloxamer Polymers 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 229920001577 copolymer Polymers 0.000 description 12
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 11
- 229960000502 poloxamer Drugs 0.000 description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102000011931 Nucleoproteins Human genes 0.000 description 7
- 108010061100 Nucleoproteins Proteins 0.000 description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 238000011510 Elispot assay Methods 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 5
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- SCFRNIGTNIZSLS-UHFFFAOYSA-M 3-acetyloxypropyl-(2,3-dioctoxypropyl)-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCOCC(C[N+](C)(C)CCCOC(C)=O)OCCCCCCCC SCFRNIGTNIZSLS-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- IPLARLLCRRKZML-UHFFFAOYSA-M 2-acetyloxyethyl-(2,3-dihexoxypropyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCOCC(C[N+](C)(C)CCOC(C)=O)OCCCCCC IPLARLLCRRKZML-UHFFFAOYSA-M 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- KGKPWXCCILJTPY-UHFFFAOYSA-M benzyl-(2,3-dihexoxypropyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCOCC(OCCCCCC)C[N+](C)(C)CC1=CC=CC=C1 KGKPWXCCILJTPY-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002901 sodium glycerophosphate Drugs 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 description 1
- OFBLZCXWVROESG-PKPIPKONSA-N (2s)-1,2,3-trihydroxyheptan-4-one Chemical compound CCCC(=O)C(O)[C@@H](O)CO OFBLZCXWVROESG-PKPIPKONSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- NRWMBHYHFFGEEC-KTKRTIGZSA-N (9Z)-1-O-octadec-9-enyl glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-KTKRTIGZSA-N 0.000 description 1
- QNPBWACMHMATDF-WRBBJXAJSA-N (9z,29z)-19-[(dimethylamino)methyl]-20-(2-hydroxyethylamino)octatriaconta-9,29-diene-18,21-dione Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)C(CN(C)C)C(NCCO)C(=O)CCCCCCC\C=C/CCCCCCCC QNPBWACMHMATDF-WRBBJXAJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- MNZPFYUUDBYKMD-UHFFFAOYSA-N 2,3,4,5,6-pentachlorophenol;hydrochloride Chemical compound Cl.OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl MNZPFYUUDBYKMD-UHFFFAOYSA-N 0.000 description 1
- LBYIQAJLTHFLEB-UHFFFAOYSA-M 2,3-didodecoxypropyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCC LBYIQAJLTHFLEB-UHFFFAOYSA-M 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- PWTNRNHDJZLBCD-UHFFFAOYSA-N 2-(2-pentoxyethoxy)ethanol Chemical compound CCCCCOCCOCCO PWTNRNHDJZLBCD-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- MUTSEBWUTOGGIW-UHFFFAOYSA-M 2-benzoyloxyethyl-(2,3-dihexoxypropyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCOCC(OCCCCCC)C[N+](C)(C)CCOC(=O)C1=CC=CC=C1 MUTSEBWUTOGGIW-UHFFFAOYSA-M 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- AYULJTSFTOUUSL-UHFFFAOYSA-M 3-aminopentyl-tri(dodecan-2-yloxy)azanium;bromide Chemical compound [Br-].CCCCCCCCCCC(C)O[N+](CCC(N)CC)(OC(C)CCCCCCCCCC)OC(C)CCCCCCCCCC AYULJTSFTOUUSL-UHFFFAOYSA-M 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101001064302 Homo sapiens Lipase member I Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100030659 Lipase member I Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- KSXARDZWGVRJBS-UHFFFAOYSA-N [2-(2-dodecan-2-yloxyethyl)piperazin-1-yl]azanium bromide Chemical compound [Br-].CCCCCCCCCCC(C)OCCC1CNCCN1[NH3+] KSXARDZWGVRJBS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- SMTUJUHULKBTBS-UHFFFAOYSA-N benzyl(trimethyl)azanium;methanolate Chemical compound [O-]C.C[N+](C)(C)CC1=CC=CC=C1 SMTUJUHULKBTBS-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- 229940115457 cetyldimethylethylammonium bromide Drugs 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 150000002334 glycols Polymers 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- UMWKZHPREXJQGR-XOSAIJSUSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]decanamide Chemical compound CCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UMWKZHPREXJQGR-XOSAIJSUSA-N 0.000 description 1
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- KMVDECFGXJKYHV-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C KMVDECFGXJKYHV-UHFFFAOYSA-L 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant.
- a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.
- non-ionic block copolymers as adjuvants in polynucleotide based medicaments has been documented in the art.
- Polynucleotide complexes which comprise a polynucleotide, a block copolymer and a cationic surfactant have demonstrated enhanced in vivo immune response.
- One method of drying an aqueous medium is by lyophilization in which the medium is frozen and then the water is extracted by sublimation under vacuum.
- the aqueous medium contains a suspension of microparticles
- these microparticles tend to cluster during the initial freezing step of the lyophilization process due to the propagation of the crystallization front.
- the microparticles become permanently aggregated and do not redisperse when reconstituted, creating a population with a very polydisperse size distribution.
- the invention provides a method of preparing a lyophilized composition
- a method of preparing a lyophilized composition comprising mixing a block copolymer with a population of polynucleotide molecules, a cationic surfactant, and an amorphous cryoprotectant or a bulking agent or any combination thereof, at a temperature below the cloud point of the block copolymer to form a mixture.
- This mixture is then frozen and finally dried under vacuum. Upon reconstitution of this mixture, the particle size and population polydispersity are maintained.
- the composition comprising a polynucleotide, a block copolymer and a cationic surfactant are mixed at a temperature below the cloud point of the block copolymer, at a temperature of about ⁇ 2° C. to about 8° C.
- the mixture prior to lyophilization, is cold filtered, thereby rendering it sterile.
- this cold filtration step is performed at a temperature of about ⁇ 2° C. to about 8° C. using a filter with a pore size of about 0.01 microns to about 2 microns.
- Block copolymers such as polyoxyethylene (POE)/polyoxypropylene (POP) are desired.
- An example of a useful block copolymer is Poloxamer CRL-1005.
- Suitable cationic surfactants for use in the present invention include benzalkonium chloride and ( ⁇ )-N-(3-Acetoxypropyl)-N,N-dimethyl-2,3-bis(octyloxy)-1-propanaminium chloride (Pr-DoctRIe-OAc).
- Suitable amorphous cryoprotectants and crystalline bulking agents include the following sugars: sucrose, lactose, trehalose, maltose or glucose, wherein the solution comprises about 1% to about 20% (w/v) sugar.
- a suitable embodiment of the invention contains about 10% sucrose.
- the composition may also optionally comprise a pH stabilizing buffer.
- the present invention also encompasses the polynucleotide/block copolymer/cationic surfactant microparticles produced by the lyophilization processes described herein.
- FIG. 1A and FIG. 1B are graphs plotting the Z average mean particle size and polydispersity of reconstituted lyophilized microparticles produced by the method described in Example 1.
- FIG. 2 contains the structures of the following cationic lipids: Benzalkonium chloride (BAK C12), ( ⁇ )-N-(Benzyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (Bn-DHxRIE), ( ⁇ )-N-(2-Acetoxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OAc), ( ⁇ )-N-(2-Benzoyloxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanraminium bromide (DHxRIE-OBz) and ( ⁇ )-N-(3-Acetoxypropyl)-N,N-dimethyl-2,3-bis(octyloxy)-1-propanaminium chloride (Pr-DOctRIE-OAc).
- BAK C12
- PBS refers to—phosphate buffered saline—.
- BAK refers to—benzalkonium chloride—.
- BEC refers to—benzethonium chloride
- CPC refers to—cetylpyridinium chloride—.
- CAC cetyl trimethyl-ammonium chloride
- PS-80 refers to—polysorbate 80—.
- cloud point refers to the point in a temperature shift, or other titration, at which a clear solution becomes cloudy, i.e., when a component dissolved in a solution begins to precipitate out of solution.
- the term “adjuvant” is any substance or combination of substances which nonspecifically enhances the immune response to an antigen; and also relates to any substance which enhances the immune response directly related to delivery of a polynucleotide within a vertebrate or mammalian host, such as a human or non-human mammalian host, such that administration of the adjuvant in combination with the polynucleotide results in an increased in vivo immune response to expression of the intended antigen or antigens encoded by the polynucleotide. Included in this definition are substances which may act as facilitators of gene delivery, thereby increasing the amount of plasmid DNA delivered to cells that can express the intended antigen.
- Substances which may enhance delivery of plasmid DNA would include those which do not substantially interact with the plasmid DNA in the formulation and substances which do interact with the plasmid DNA, forming tightly bound or weakly bound complexes between the adjuvant and the plasmid DNA, either in vitro or in vivo.
- polynucleotide is a nucleic acid molecule which contains essential regulatory elements such that upon introduction into a living, vertebrate cell, the nucleic acid molecule is able to direct the cellular machinery to produce translation products encoded by the genes comprising the nucleic acid molecule.
- polynucleotide medicament is used to indicate polynucleotide-based compositions, including compositions which comprise the poloxamers and cationic surfactants disclosed herein, useful as a vehicle to deliver a transgene of interest to a vertebrate host, such as a human or non-human mammalian host, or to provide or promote detectable and/or therapeutic levels of expression of the transgene, and/or to generate or promote an immune response to the expression product of the transgene.
- a vertebrate host such as a human or non-human mammalian host
- vector refers to a vehicle by which DNA fragments, most likely comprising a transgene or portion thereof which expresses an antigen or antigenic epitope, can be introduced into a host organism or host tissue.
- vectors include but are not limited to recombinant vectors, including DNA plasmid vectors, recombinant viral vectors such as adenovirus vectors, retrovirus vectors and adeno-associated virus vectors, as well as bacteriophage vectors and cosmid vectors.
- gene refers to a segment of a nucleic acid molecule which encodes a discrete protein or a portion thereof, such as a portion of the full-length protein which will induce an appropriate immune response within the host.
- amorphous cryoprotectant refers to a compound which, when included in the formulations of the present invention during freezing or lyophilization under given conditions, does not form crystals. It is specifically intended that compounds that are known to form crystals under certain lyophilization conditions but not under others are included within the term “amorphous cryoprotectant,” so long as they remain amorphous under the specific freezing or lyophilization conditions to which they are subjected.
- cryoprotectant may be used interchangeably with the term “amorphous cryoprotectant” herein.
- crystalline bulking agent refers to a compound which, when included in the formulations of the present invention during freezing or lyophilization under given conditions, forms crystals. It is specifically intended that compounds that are known to form crystals under certain lyophilization conditions but not under others are included within the term “crystalline bulking agent,” so long as they crystallize under the specific freezing or lyophilization conditions to which they are subjected.
- the term “bulking agent” may be used interchangeably with the term “crystalline bulking agent” herein.
- lyophilization is a means of drying, achieved by freezing a wet substance at a temperature from about ⁇ 172° C. to about ⁇ 2° C. followed by rapid dehydration by sublimation under a vacuum level down to the lower level of a diffusion pump.
- a useful pressure range is from about 0.1 mTorr to about 0.5 Torr.
- freeze-drying may be used interchangeably with the term “lyophilization” herein.
- the present invention relates to novel methods for lyophilizing a formulation suitable for use in polynucleotide based medicaments.
- the methods result in formulations comprising polynucleotide molecules, block copolymer, and a cationic surfactant that upon reconstitution maintain the same particle size and polydispersity prior to freeze-drying.
- the method of the present invention comprises mixing: (i) a cationic surfactant; (ii) a block copolymer; and (iii) a polynucleotide; at a temperature below the cloud point of said block copolymer to form a mixture.
- the order in which components of the mixture are added may vary.
- a suitable order in which ingredients of the mixture may be added include, but is not limited to, (i) polynucleotide; (ii) block copolymer; and (iii) cationic surfactant.
- the order of addition can also include: (i) cationic surfactant; (ii) block copolymer; and (iii) polynucleotide. Stirring of the mixture can occur once all components have been added, concurrently while components are being added, or in between the addition of components.
- the block copolymers useful in the polynucleotide based medicaments described herein are block copolymers which form microparticles at room temperature (above the block copolymer cloud point) and may associate with a population of nucleic acid molecules, such as a population of plasmid DNA molecules, with and without the addition of cationic surfactants.
- the nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA) as well as a ribonucleic acid molecule (RNA).
- a suitable group of copolymers used in the methods of the present invention include non-ionic block copolymers which comprise blocks of polyoxyethylene (POE) and polyoxypropylene (POP).
- suitable non-ionic block copolymers include polyoxyethylene (POE)/polyoxypropylene (POP) block copolymers, especially higher molecular weight POE-POP-POE block copolymers.
- POE polyoxyethylene
- POP polyoxypropylene
- these non-ionic block copolymers have the following general formula: HO(C 2 H 4 O) x (C 3 H 6 O) y (C 2 H 4 O) x H wherein (y) represents a number such that the molecular weight of the hydrophobic POP portion (C 3 H 6 O) is up to approximately 20,000 daltons and wherein (x) represents a number such that the percentage of hydrophilic POE portion (C 2 H 4 O) is between approximately 1% and 50% by weight.
- a suitable POE-POP-POE block copolymer that can be used in the invention has the following formula HO(C 2 H 4 O) x (C 3 H 6 O) y (C 2 H 4 O) x H wherein (y) represents a number such that the molecular Weight of the hydrophobe (C 3 H 6 O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is between approximately 3% and 35%.
- Another suitable POE-POP-POE block copolymer that can be used in the invention has the following formula: HO(C 2 HO) x (C 3 H 6 O) y (C 2 H 4 O) x H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is between approximately 3% and 10%.
- a typical POE/POP block copolymer utilized herein will comprise the structure of POE-POP-POE, as reviewed in Newman et al. Critical Reviews in Therapeutic Drug Carrier Systems 15 (2): 89-142 (1998).
- a suitable block copolymer for use in the methods of the present invention is a POE-POP-POE block copolymer with a central POP block having a molecular weight in a range from under 1000 daltons up to approximately 20,000 daltons and flanking POE blocks which comprise up to about 50% of the total molecular weight of the copolymer.
- Block copolymers such as these, which are much larger than earlier disclosed Pluronic-based POE/POP block copolymers, are described in detail in U.S. Reissue Pat.
- CRL-1005 is another suitable surface-active copolymer that can be used in the invention and has the following formula: HO(C 2 H 4 O) x (C 3 H 6 O) y (C 2 H 4 O) x H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 12,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is approximately 5%. In the case of CRL-1005, (x) is about 7, ⁇ 1 and (y) is approximately 12,000 Daltons, with about 207 units, ⁇ 7.
- the measurement of surface charge (zeta potential) and the amount of DNA associated with CRL-1005 particles are consistent with a model for the interaction of plasmid DNA/the block copolymer (CRL-1005) and the cationic surfactant (for example, BAK).
- the model suggests that BAK associating with particles of CRL-1005, through hydrophobic interactions, results in a reduction of the CRL-1005 particle size and in the formation of positively charged CRL-1005 particles.
- Plasmid DNA polynucleotide
- BAK positively charged headgroup of the cationic surfactant
- CTL-1005 block copolymer
- An alternative surface-active copolymer that can be used in the invention has the following formula: HO(C 2 H 4 O) x (C 3 H 6 O) y (C 2 H 4 O) x H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 9,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is approximately 3-5%.
- Another suitable surface-active copolymer that can be used in the invention has the following formula: HO(C 2 H 4 O) x (C 3 H 6 O) y (C 2 H 4 O) x H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 9,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is approximately 3%.
- the present invention relates to a method for producing a lyophilized formulation suitable for use in polynucleotide based medicaments comprising a block copolymer which is Poloxamer CRL-1005.
- block copolymers for use in the present invention include “reverse” block copolymers wherein the hydrophobic portions of the molecule (C 3 H 6 O) and the hydrophilic portions (C 2 H 4 O) have been reversed such that the polymer has the formula: HO(C 3 H 6 O) y (C 2 H 4 O) x (C 3 H 6 O) y H wherein (y) represents a number such that the molecular weight of the hydrophobic POP portion (C 3 H 6 O) is up to approximately 20,000 daltons and wherein (x) represents a number such that the percentage of hydrophilic POE portion (C 2 H 4 O) is between approximately 1% and 50% by weight.
- These “reverse” block copolymers have the structure POP-POE-POP and are described in U.S. Pat. Nos. 5,656,611 and 6,359,054.
- a suitable POP-POE-POP block copolymer that can be used in the invention has the following formula: HO(C 3 H 6 O) y (C 2 H 4 O) x (C 3 H 6 O) y H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is between approximately 3% and 35%.
- POP-POE-POP block copolymer that can be used in the invention has the following formula: HO(C 3 H 6 O) y (C 2 H 4 O) x (C 3 H 6 O) y H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is between approximately 3% and 10%.
- Another suitable surface-active copolymer that can be used in the invention and has the following formula: HO(C 3 H 6 O) y (C 2 H 4 O) x (C 3 H 6 O) y H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 12,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is approximately 5%.
- An alternative surface-active copolymer that can be used in the invention has the following formula: HO(C 3 H 6 O) y (C 2 H 4 O) x (C 3 H 6 O) y H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 9,000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is approximately 3-5%.
- Another suitable surface-active copolymer that can be used in the invention has the following formula: HO(C 3 H 6 O) y (C 2 H 4 O) x (C 3 H 6 O) y H wherein (y) represents a number such that the molecular weight of the hydrophobe (C 3 H 6 O) is approximately 9000 Daltons and (x) represents a number such that the percentage of hydrophile (C 2 H 4 O) is approximately 3%.
- the block copolymers for use in the invention are amphipathic compounds with inverse solubility characteristics in aqueous media. Below their cloud points (1-20° C.), these copolymers are water-soluble and form clear solutions that can be filter sterilized.
- the solution process involves the formation of hydrogen bonds between oxygen atoms and hydroxyl groups in the copolymer and water molecules. When a solution of copolymer is warmed and passes through its cloud point, the increased thermal motion is sufficient to break the hydrogen bonds and as the copolymer comes out of solution, they self-assemble into microparticles (See Todd, C. W., et al. Vaccine 15. 564-570 (1997) and Todd, C. W., et al. Dev. Biol. Stand. 92: 343-353 (1997)). The process is reversible.
- any type of polynucleotide can be incorporated into the method of the current invention.
- plasmid DNA genomic DNA, cDNA, DNA fragments and RNA.
- Certain formulations of the present invention include a cocktail of plasmids.
- Various plasmids desired in a cocktail are combined together in PBS or other diluent prior to addition to the other ingredients.
- plasmids may be present in a cocktail at equal proportions, or the ratios may be adjusted based on, for example, relative expression levels of the antigens or the relative immunogenicity of the encoded antigens.
- various plasmids in the cocktail may be present in equal proportion, or 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times as much of one plasmid may be included relative to other plasmids in the cocktail.
- the polynucleotide formulations produced by the methods of the present invention also comprise a cationic surfactant. It will be known to one of skill in the art that numerous cationic surfactants may be a candidate for use in these formulations. Therefore, the invention contemplates use of any cationic surfactant which, along with a block copolymer, and a polynucleotide promotes generation of a particle size and surface charge as described herein.
- Cationic surfactants which may be used include, but are not limited to, benzalkonium chloride (BAK), benzethonium chloride, cetramide (which contains tetradecyltrimethylammonium bromide and possibly small amounts of dedecyltrimethylammonium bromide and hexadecyltrimethyl ammonium bromide), cetylpyridinium chloride (CPC) and cetyl trimethylammonium chloride (CTAC), primary amines, secondary amines, tertiary amines, including but not limited to N,N′,N′-polyoxyethylene (10)-N-tallow-1,3-diaminopropane, other quaternary amine salts, including but not limited to dodecyltrimethylammonium bromide, hexadecyltrimethyl-ammonium bromide, mixed alkyl-trimethyl-ammonium bromide, benzyldimethyldodecyl
- cetylpyridinium bromide and cetylpyridinium chloride N-alkylpiperidinium salts, dicationic bolaform electrolytes (C 12 Me 6 ; C 12 Bu 6 ), dialkylglycetylphosphorylcholine, lysolecithin, L-adioleoyl phosphatidylethanolamine, cholesterol hemisuccinate choline ester, lipopolyamines, including but not limited to dioctadecylamidoglycylspermine (DOGS), dipalmitoyl phosphatidylethanol-amidospermine (DPPES), lipopoly-L (or D)-lysine (LPLL, LPDL), poly (L (or D)-lysine conjugated to N-glutarylphosphatidylethanolamine, didodecyl glutamate ester with pendant amino group (C 12 GluPhCnN + ), ditetradecyl glutamate ester with pendant amino group
- cationic surfactants for use in the invention are selected from the group of cationic lipids including N-(3-aminopropyl)-N,N-(bis-(2-tetradecyloxyethyl))-N-methyl-ammonium bromide (PA-DEMO), N-(3-aminopropyl)-N,N-(bis-(2-dodecyloxyethyl))-N-methyl-ammonium bromide (PA-DELO), N,N,N-tris-(2-dodecyloxy)ethyl-N-(3-amino)propyl-ammonium bromide (PA-TELO), and N 1 -(3-aminopropyl)((2-dodecyloxy)ethyl)-N 2 -(2-dodecyloxy)ethyl-1-piperazinaminium bromide (GA-LOE-BP), DL-1,2-dode
- Suitable, but non-limiting cationic lipids for use in certain embodiments of the present invention include DMRIE (( ⁇ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide), GAP-DMORIE (( ⁇ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradeceneyloxy)-1-propanaminium bromide), and GAP-DLRIE (( ⁇ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-dodecyloxy)-1-propanaminium bromide).
- DMRIE (( ⁇ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide)
- GAP-DMORIE
- cationic lipids for use in the present invention include the compounds described in U.S. Pat. Nos. 5,264,618, 5,459,127 and 5,994,317.
- Non-limiting examples of these cationic lipids include ( ⁇ )-N,N-dimethyl-N-[2-(sperminecarboxamido)ethyl]-2,3-bis(dioleyloxy)-1-pr opaniminium pentahydrochloride (DOSPA), ( ⁇ )-N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propaniminium bromide ( ⁇ -aminoethyl-DMRIE or ⁇ AE-DMRIE) and ( ⁇ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propaniminium bromide (GAP-DLRIE).
- DMRIE-derived cationic lipids that are useful in the present invention include ( ⁇ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-decyloxy)-1-propanaminium bromide (GAP-DDRIE), ( ⁇ )-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-tetradecyloxy)-1-propanaminium bromide (GAP-DMRIE), ( ⁇ )-N-((N′′-methyl)-N′-ureyl)propyl-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (GMU-DMRIE), ( ⁇ )-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (DLRIE), and ( ⁇ )-N-(2-hydroxy)-
- the cationic surfactant is selected from the group consisting of benzalkonium chloride, benzethonium chloride, cetramide, cetylpyridinium chloride and cetyl trimethylammonium-chloride.
- Benzalkonium chloride is available commercially and is known to exist as a mixture of alkylbenzyldimethylammonium chlorides of the general formula: [C 6 H 5 CH 2 N(CH 3 )2R] C1, where R represents a mixture of alkyls, including all or some of the group beginning with n-C 8 H 17 through n-C 16 H 33 .
- the average MW of BAK is 360 (see Handbook of Pharmaceutical Excipients, Ed.
- Benzethonium chloride is N,N-dimethyl-N-[2-[2-[4-(1,1,3,3tetramethylbutyl)phenoxy]ethoxy]ethyl]benzene-methanaminium chloride (C 27 H 42 CINO 2 ), which has a molecular weight of 448.10 ( Handbook of Pharmaceutical Excipients at page 30-31).
- Cetramide consists mainly of trimethyltetradecylammonium bromide (C 17 H 38 BrN), which may contain smaller amounts of dodecyltrimethyl-ammonium bromide (C 15 H 34 BrN) and hexadecyltrimethylammonium bromide (C 19 H 42 BrN), and has a molecular weight of 336.40 ( Handbook of Pharmaceutical Excipients at page 96-98).
- the cationic surfactant for use in the methods of the current invention is selected from the group consisting of ( ⁇ )-N-(Benzyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (Bn-DHxRIE), ( ⁇ )-N-(2-Acetoxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OAc), ( ⁇ )-N-(2-Benzoyloxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OBz) and ( ⁇ )-N-(3-Acetoxypropyl)-N,N-dimethyl-2,3-bis(octyloxy)-1-propanaminium chloride (Pr-DOctRIE-OAc).
- Bn-DHxRIE ⁇ -N
- Auxiliary agents for use in compositions of the present invention include, but are not limited to, non-ionic detergents and surfactants IGEPAL CA 630® CA 630, NONIDET NP-40, Nonidet® P40, Tween-20®, Tween-80®, Triton X-100TM, and Triton X-114TM; the anionic detergent sodium dodecyl sulfate (SDS); the sugar stachyose; the condensing agent DMSO; and the chelator/DNAse inhibitor EDTA.
- the auxiliary agent is DMSO, Nonidet P40®. See, e.g., U.S. Patent Application Publication 20020019358, published Feb. 14, 2002, which is incorporated herein by reference in its entirety.
- polynucleotide formulations produced by the methods of the present invention may also optionally include a non-ionic surfactant, such as polysorbate-80, which may be a useful excipient to control particle aggregation in the presence of the polynucleotide.
- a non-ionic surfactant such as polysorbate-80
- Additional non-ionic surfactants are known in the art and may be used to practice this portion of the invention.
- non-ionic surfactants include, but are not limited to, other polysorbates, -Alkylphenyl polyoxyethylene ether, n-alkyl polyoxyethylene ethers (e.g., TritonsTM), sorbitan esters (e.g., SpansTM), polyglycol ether surfactants (TergitolTM), polyoxyethylenesorbitan (e.g., TweensTM), poly-oxyethylated glycol monoethers (e.g., BrijTM, polyoxylethylene 9 lauryl ether, polyoxyethylene 10 ether, polyoxylethylene 10 tridecyl ether), lubrol, perfluoroalkyl polyoxylated amides, N,N-bis[3D-gluconamidopropyl]cholamide, decanoyl-N-methylglucamide, -decyl ⁇ -D-glucopyranozide, n-decyl ⁇ -D-glucopyranozide,
- the present invention relates to methods for lyophilizing a formulation suitable for use in polynucleotide based medicaments such that upon reconstitution, the particle size and population polydispersity of the microparticles remain unchanged.
- the methods result in the generation of microparticles (at temperatures above the cloud point of CRL-1005, or another representative block copolymer) which comprise a block copolymer and cationic surfactant in contact with polynucleotide molecules.
- the components which will eventually comprise the microparticles are mixed with an amorphous cryoprotectant or a crystalline bulking agent by stirring at temperature below the cloud point of the block copolymer. Additionally, the mixture may also comprise a pH stabilizing buffer.
- each component of this mixture must be thoroughly co-dissolved at a temperature below the cloud point of the polymer.
- This solution can also be sterilized via cold filtration and aliquoted into sterile vials prior to lyophilization.
- the freeze-dried formulation Prior to administration to a patient by injection, or any other means, the freeze-dried formulation can be reconstituted and the vial can be brought to room temperature or to a temperature above the cloud point of the block copolymer, wherein microparticle formation will occur during the warming process. It is the discovery of the current inventors that microparticle reconstitution results in particles with a particle size and a population polydispersity that remains unchanged during the freeze-drying process. This is further illustrated in Examples 1 and 2.
- Table 1 indicates the mean average diameter of microparticles composed of polynucleotide, poloxamer CRL-1005 and BAK co-dissolved in solutions of both PBS and 10% sucrose/10 mM sodium phosphate.
- the microparticles prepared in PBS have a much larger polydispersity following reconstitution than prior to freeze-drying indicating a broad size range of particles.
- the microparticles co-dissolved in 10% sucrose/10 mM sodium phosphate demonstrate virtually the same polydispersity before lyophilization and after reconstitution, indicating a narrow size distribution.
- FIGS. 1A and 1B demonstrate that particle size and polydispersity remain unchanged after 6 hours at room temperature following reconstitution.
- the lyophilized composition of the present invention may be reconstituted in any aqueous solution which produces a stable, mono-dispersed solution suitable for administration.
- aqueous solutions include, but are not limited to: sterile water, PBS or saline.
- a polynucleotide is mixed with the poloxamer CRL-1005, BAK (Benzalkonium chloride 50% solution, available from Ruger Chemical Co. Inc.) and an amorphous cryoprotectant or crystalline bulking agent. Additionally, the mixture may also comprise a pH stabilizing buffer. Suitable final concentrations of each component of the formulae are described in the examples, but for any of these methods, the concentrations of each component may be varied by basic stoichiometric calculations known by those of ordinary skill in the art to make a final solution having the desired concentrations.
- the concentration of the block copolymer is adjusted depending on, for example, transfection efficiency, expression efficiency, or immunogenicity.
- the final concentration of the block copolymer is between about 1 mg/mL to about 75 mg/mL.
- the final concentration of the block copolymer is between about 3 mg/mL to about 50 mg/mL, about 5 mg/mL to about 40 mg/mL, about 6 mg/mL to about 30 mg/mL.
- the block copolymer For example, about 6 mg/mL, about 6.5 mg/mL about 7 mg/mL, about 7.5 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, or about 30 mg/mL of the block copolymer.
- the concentration of the poloxamer CRL-1005 is adjusted depending on, for example, transfection efficiency, expression efficiency, or immunogenicity.
- the final concentration of the poloxamer CRL-1005 is between about 1 mg/mL to about 75 mg/mL.
- the final concentration of the poloxamer CRL-1005 is between about 3 mg/mL to about 50 mg/mL, about 5 mg/mL to about 40 mg/mL, about 6 mg/mL to about 30 mg/mL.
- the concentration of DNA in the methods of the current invention is adjusted depending on many factors, including the amount of a formulation to be delivered, the age and weight of the subject, the delivery method and route and the immunogenicity of the antigen being delivered.
- the final concentration of DNA is from about 1 mg/mL to about 30 mg/mL of plasmid (or other polynucleotide).
- a formulation of the present invention may have a final concentration of DNA from about 0.1 mg/mL to about 20 mg/mL, or about 1 mg/mL to about 10 mg/mL.
- the final DNA concentration may be about 1 mg/mL, about 2 mg/mL, about 2.5 mg/mL, about 3 mg/mL, about 3.5 mg/mL, about 4 mg/mL, about 4.5 mg/mL, about 5 mg/mL, about 5.5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, or about 20 mg/mL.
- the concentration of the cationic surfactant may be adjusted depending on, for example, a desired particle size and improved stability.
- the methods of the present invention include CRL-1005 and DNA, but are free of cationic surfactant.
- cationic surfactant-containing formulations of the present invention are adjusted to have a final concentration of cationic surfactant from about 0.01 mM to about 5 mM.
- a formulation of the present invention may have a final cationic surfactant concentration of about 0.06 mM to about 1.2 mM, or about 0.1 mM to about 1 mM, or about 0.2 mM to about 0.7 mM.
- a formulation of the present invention may have a final cationic surfactant concentration of about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, or about 0.7 mM.
- the concentration of BAK may be adjusted depending on, for example, a desired particle size and improved stability.
- the methods of the present invention include CRL-1005 and DNA, but are free of BAK.
- BAK-containing formulations of the present invention are adjusted to have a final concentration of BAK from about 0.01 mM to about 5 mM.
- a formulation of the present invention may have a final BAK concentration of about 0.06 mM to about 1.2 mM, or about 0.1 mM to about 1 mM, or about 0.2 mM to about 0.7 mM.
- a formulation of the present invention may have a final BAK concentration of about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, or about 0.7 mM.
- the total volume of the formulations produced by the methods of the current invention may be scaled up or down, by choosing apparatus of proportional size.
- the three components of the formulation, BAK, CRL-1005, and plasmid DNA may be added in any order.
- the polynucleotide based medicaments produced by the methods of the present invention may be formulated in any pharmaceutically effective formulation for host administration. It will be useful to utilize pharmaceutically acceptable formulations which also provide long-term stability of the polynucleotide based medicaments of the present invention.
- DNA plasmids undergo a physiochemical change in which the supercoiled plasmid converts to the open circular and linear form. A variety of storage conditions (low pH, high temperature, low ionic strength) can accelerate this process.
- the removal and/or chelation of trace metal ions from the DNA plasmid solution, from the formulation buffers or from the vials and closures, stabilizes the DNA plasmid from this degradation pathway during storage.
- the particles formed by the current method are from about 100 nm to about 2000 nm in diameter.
- the non-ionic block copolymer particle in the presence of the cationic surfactant will have a positive surface charge whereas the polymer particle in the presence of cationic surfactant and DNA should have a surface charge significantly more negative than the polymer particle alone.
- the exemplified microparticles described in the Example sections range from about 200-600 nm in diameter with a slightly positive zeta potential measurement in the presence of BAK but without addition of the polynucleotide (about 2.5 mV for CRL-1005 and 0.71 mM BAK) and a negative zeta potential when the polynucleotide (at 5 mg/mL) is present (about ⁇ 46.6 mV for CRL-1005 and 0.71 mM BAK and 5 mg/mL plasmid DNA). While these values are instructive, they are by no way limiting.
- a cationic surfactant changes the configuration or structural integrity of the particle, which in turn increases the ability of the altered structure to better interact with polynucleotide molecules. Therefore, while ranges of surface charge and size measurements of various particles may be instructive, they are not necessarily limiting.
- concentrations of one type of block copolymer and one type of cationic surfactant can adjust concentrations of one type of block copolymer and one type of cationic surfactant to form distinct microparticles, wherein the microparticles are ultimately characterized by an increased ability to associate with a specific population of polynucleotide molecules.
- the formulation produced by the methods of the current invention may be aliquoted into a suitable container for storage.
- suitable containers include, but are not limited to, glass vials, glass bottles, syringes, sterilizable plastic bags, polyethylene tubes, vials or bottles, and polypropylene tubes, vials or bottles and any other container suitable for manufacturer bulk use or in the preparation of a kit comprising the polynucleotide based medicaments of the invention.
- the method of the present invention also relates to mixing a cationic surfactant, a block copolymer, a population of polynucleotide molecules and an amorphous cryoprotectant or a crystalline bulking agent and any combination thereof at a temperature above the cloud point of said block copolymer.
- the cloud point is dependent upon the block copolymer used in the mixture of the current invention. However, the suitable cloud point can range from about 1° C. to about 20° C.
- the temperature at which the mixture of the current invention is mixed can range from about 8° C. to about 35° C.
- the present invention also relates to a polynucleotide based medicament formulation which first comprises a polynucleotide, an adjuvant component comprising a block copolymer, a cationic surfactant and an amorphous cryoprotectant or a crystalline bulking agent, as described within this specification, and secondly comprising a non-ionic surfactant, such as polysorbate-80 or other excipients, including but not limited to excipients known in the art such as glycerol or propylene glycol, or a non-ionic surfactant listed herein.
- a non-ionic surfactant such as polysorbate-80 or other excipients, including but not limited to excipients known in the art such as glycerol or propylene glycol, or a non-ionic surfactant listed herein.
- a formulation comprising a polynucleotide, a block copolymer, a cationic surfactant and an amorphous cryoprotectant or a crystalline bulking agent are co-solubilized at a temperature below the cloud point of the block copolymer.
- This cryoprotectant or bulking agent provides stability to the polynucleotide formulation during the freeze-drying process and subsequent reconstitution.
- stability it is meant that average size and size distribution are not affected, i.e. that little or no fusion or aggregation is observed upon reconstitution.
- Amorphous cryoprotectants which are suitable for use herein include inter alia, mono, di, or oligosaccharides, polyols, and proteins such as albumin; disaccharides such as sucrose and lactose; monosaccharides such as fructose, galactose and glucose; poly alcohols such as glycerol and sorbitol; and hydrophilic polymers such as polyethylene glycol.
- the amorphous cryoprotectant is suitably added to the formulations of the present invention before freezing, in which case it can also serve as a bulking agent. However, as a hydrophilic component, it may also provide for enhanced liquid stability.
- crystalline bulking agents such agents are often used in the preparation of pharmaceutical compositions to provide the necessary bulk upon lyophilization.
- Many types of crystalline bulking agents are known in the art. (See, Martini et al. PDA J. Pharm Sci Tech 51(2):62-61, 1997).
- Exemplary crystalline bulking agents include D-mannitol, trehalose, and dextran.
- a crystalline bulking agent is generally defined as a compound which can exist in a crystalline form and whose glass transition point (Tg) is below the temperature at which it is being freeze-dried.
- Tg glass transition point
- a conventional freeze-dryer operates at a shelf-temperature from between about ⁇ 10° C. to about ⁇ 50° C. Therefore, in one embodiment, a crystalline bulking agent has a Tg below about ⁇ 50° C.
- the solution comprises about 1% to about 20% (w/v) of the amorphous cryoprotectant or crystalline bulking agent. In a suitable embodiment, the solution contains about 3% to about 17%, about 5% to about 15% or about 8% to about 12% (w/v) amorphous cryoprotectant or crystalline bulking agent. For example about 8%, about 9%, about 10%, about 11%, or about 12% (w/v) amorphous cryoprotectant or crystalline bulking agent.
- cryoprotectants and bulking agents from the group consisting of, but not limited to the following sugars: sucrose, lactose, trehalose, maltose or glucose.
- the solution comprises about 1% to about 20% (w/v) sugar.
- the solution contains about 3% to about 17%, about 5% to about 15% or about 8% to about 12% (w/v) sugar. For example about 8%, about 9%, about 10%, about 11%, or about 12% (w/v) sugar.
- the solution contains about 1% to about 20% (w/v) sucrose. In a suitable embodiment, the solution contains about 3% to about 17%, about 5% to about 15% or about 8% to about 12% (w/v) sucrose. For example about 8%, about 9%, about 10%, about 11%, or about 12% (w/v) sucrose. In yet another suitable embodiment, the solution contains about 10% (w/v) sucrose.
- a formulation comprising a polynucleotide, a block copolymer, a cationic surfactant, an amorphous cryoprotectant or a crystalline bulking agent and a pH buffering agent are co-solubilized at a temperature below the cloud point of the block copolymer.
- the solution comprising a block copolymer, cationic surfactant, polynucleic acid and amorphous cryoprotectant or crystalline bulking agent also contains a physiologic buffer that maintains the solution pH within the range of about pH 4.0 to about pH 9.0.
- the pH of the co-solubilized mixture is about pH 5.0 to about pH 8.0, about pH 6.0 to about pH 8.0, or about pH 7.0 to about pH 7.5.
- the pH of the co-solubilized mixture is about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, about pH 7.4 or about pH 7.5.
- pH buffering agents suitable for use in the invention include, but are not limited to, saline, PBS, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 3-(N-Morpholino)propanesulfonic acid (MOPS), 2-bis(2-Hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol (BIS-TRIS), potassium phosphate (KP), sodium phosphate (NaP), dibasic sodium phosphate (Na 2 HPO 4 ), monobasic sodium phosphate (NaH2PO 4 ), monobasic sodium potassium phosphate (NaKHPO 4 ), magnesium phosphate (Mg 3 (PO 4 ) 2 —4H 2 O), potassium acetate (CH 3 COOK), D(+)- ⁇ -sodium glycerophosphate (HOCH 2 CH(OH)CH 2 OPO 3 Na
- Additional pH buffering agents for use in the invention include, a salt M-X dissolved in aqueous solution, association, or dissociation products thereof, where M is an alkali metal (e.g., Li + , Na + , K + , Rb + ), suitably sodium or potassium, and where X is an anion selected from the group consisting of phosphate, acetate, bicarbonate, sulfate, pyruvate, and an organic monophosphate ester, preferably glucose 6-phosphate or DL-a-glycerol phosphate, and other physiologic buffers known to those skilled in the art.
- M is an alkali metal (e.g., Li + , Na + , K + , Rb + )
- X is an anion selected from the group consisting of phosphate, acetate, bicarbonate, sulfate, pyruvate, and an organic monophosphate ester, preferably glucose 6-phosphate or DL-a-glycerol phosphat
- the pH buffering agent is selected from the group consisting of sodium phosphate, potassium phosphate, dibasic sodium phosphate (Na 2 HPO 4 ), monobasic sodium phosphate (NaH 2 PO 4 ), monobasic sodium potassium phosphate (NaKHPO 4 ), magnesium phosphate (Mg 3 (PO 4 ) 2 —4H 2 O), potassium acetate (CH 3 COOK), and D(+)- ⁇ -sodium glycerophosphate (HOCH 2 CH(OH)CH 2 OPO 3 Na 2 ).
- the concentration of the pH buffering agent is from about 5 mM to about 25 mM.
- a formulation of the present invention may have a final pH buffering agent concentration of about 7 mM to about 20 mM, or about 8 mM to about 15 mM, or about 9 mM to about 12 mM.
- a formulation of the present invention may have a final pH buffering agent concentration of about 9 mM, about 10 mM, about 11 mM, or about 12 mM.
- the concentration of the pH buffering agent is about 10 mM.
- the concentration of the pH buffering agent selected from sodium phosphate, potassium phosphate, Na 2 HPO 4 , NaH 2 PO 4 , NaKHPO 4 , Mg 3 (PO 4 ) 2 —4H 2 O, and HOCH 2 CH(OH)CH 2 OPO 3 Na 2 is from about 5 mM to about 25 mM.
- a formulation of the present invention may have a final concentration of pH buffering agent selected from sodium phosphate, potassium phosphate, Na 2 HPO 4 , NaH 2 PO 4 , NaKHPO 4 , Mg 3 (PO 4 ) 2 —4H 2 O, and HOCH 2 CH(OH)CH 2 OPO 3 Na 2 of about 7 mM to about 20 mM, about 8 mM to about 15 mM, or about 9 mM to about 12 mM.
- pH buffering agent selected from sodium phosphate, potassium phosphate, Na 2 HPO 4 , NaH 2 PO 4 , NaKHPO 4 , Mg 3 (PO 4 ) 2 —4H 2 O, and HOCH 2 CH(OH)CH 2 OPO 3 Na 2 of about 7 mM to about 20 mM, about 8 mM to about 15 mM, or about 9 mM to about 12 mM.
- a formulation of the present invention may have a final concentration of pH buffering agent selected from sodium phosphate, potassium phosphate, Na 2 HPO 4 , NaH 2 PO 4 , NaKHPO 4 , Mg 3 (PO 4 ) 2 —4H 2 O, and HOCH 2 CH(OH)CH 2 OPO 3 Na 2 of about 9 mM, about 10 mM, about 11 mM, or about 12 mM.
- pH buffering agent selected from sodium phosphate, potassium phosphate, Na 2 HPO 4 , NaH 2 PO 4 , NaKHPO 4 , Mg 3 (PO 4 ) 2 —4H 2 O, and HOCH 2 CH(OH)CH 2 OPO 3 Na 2 of about 9 mM, about 10 mM, about 11 mM, or about 12 mM.
- the concentration of pH buffering agent selected from sodium phosphate, potassium phosphate, Na 2 HPO 4 , NaH 2 PO 4 , NaKHPO 4 , Mg 3 (PO 4 ) 2 —4H 2 O, and HOCH 2 CH(OH)CH 2 OPO 3 Na 2 is about 10 mM. In an alternative embodiment, the concentration of sodium phosphate is about 10 mM.
- a formulation comprising a polynucleic acid, block copolymer, cationic surfactant, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then lyophilized.
- a formulation comprising a polynucleic acid, a block copolymer, cationic surfactant, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then lyophilized.
- a formulation comprising a polynucleic acid, a block copolymer, cationic surfactant, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to lyophilization.
- a formulation comprising a polynucleic acid, a block copolymer, cationic surfactant, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to lyophilization.
- the cold filtration step must take place at a temperature below the cloud point of the block copolymer comprised in the formulation.
- the cold filtration step is suitably performed at a temperature between about ⁇ 2° C. to about 8° C.
- the cold filtration step can be performed at about ⁇ 2° C., at about ⁇ 1° C., at about 0° C., at about 1° C., at about 2° C., at about 3° C., at about 4° C., at about 5° C., at about 6° C., at about 7° C. or at about 8° C.
- the filtration of the cold solution provides a cost-effective and time-efficient method by which to sterilize the solution.
- This filtration step eliminates the need to pre-sterilize the polynucleotide, block copolymer and cationic surfactant prior to mixing.
- a sterile filter with a defined pore size smaller than bacterial pathogens, the solution is sterilized.
- the pore size of the filters utilized in the cold filtration step in the present invention are suitably from about 0.01 microns to about 2 microns.
- the pore size of the filters utilized in the cold filtration step in the present invention is about 0.05 microns to about 0.25 microns.
- pore size of the filters for the cold filtration step can be about 0.05 microns, about 0.08 microns, about 0.1 microns, about 0.15 microns, about 0.16 microns, about 0.17 microns, about 0.18 microns, about 0.19 microns, about 0.2 microns, about 0.21 microns, about 0.22 microns, about 0.23 microns, about 0.24 microns, or about 0.25 microns.
- a formulation comprising a polynucleic acid, block copolymer, cationic surfactant, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- a formulation comprising a polynucleic acid, block copolymer, cationic surfactant, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then sterilized via cold filtering prior to lyophilization.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then sterilized via cold filtering prior to lyophilization.
- a formulation comprises a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- an amorphous cryoprotectant or crystalline bulking agent such as 10% (w/v) sucrose
- a formulation comprises a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids:Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc
- an amorphous cryoprotectant or crystalline bulking agent such as 10% (w/v) sucrose
- a suitable pH buffering agent such as 10 m
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DhxRIE-OBz and Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DhxRIE-OBz and Pr-DOctRIE-OAc
- an amorphous cryoprotectant or crystalline bulking agent such as 10% (w/v) sucrose
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc
- an amorphous cryoprotectant or crystalline bulking agent such as
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- Aim Prepare a DNA/poloxamer/BAK formulation (5 mg/ml DNA, 7.5 mg/mL CRL-1005, 0.3 mM BAK) in 10% sucrose, 10 mM sodium phosphate vehicle and lyophilize the formulation and determine the effect on particle size of the process.
- Apparatus A 15 ml round bottom flask, with a 3 ⁇ 8′′ ⁇ 3/16′′ egg-shaped magnetic stirrer bar (Bel-art products) and a coming stirrer/hotplate and an ice bath.
- the required volume of DNA (6.1 mg/mL DNA, VR 4700, in 10% sucrose, 10 mM Sodium phosphate), was placed into the 15 mL round bottom flask and the solution stirred with a magnetic stirrer bar, in an ice bath on top of a Corning stirrer/hotplate (speed 4, hotplate off) for 10 minutes.
- the CRL-1005 was then added using a positive displacement pipette and the solution stirred for a further 30 minutes on ice.
- the required volume of BAK solution to give a final concentration of 0.3 mM was then added drop wise, slowly, to the stirring solution over 1 minute using a iml pipette.
- the flask was then placed back into the ice bath and stirred for a further 15 minutes to produce a clear solution as the mixture cooled below the cloud point of the CRL-1005.
- the ice bath was again removed and the solution stirred for a further 15 minutes. Stirring for 15 minutes above and below the cloud point (total of 30 minutes), was defined as one thermal cycle.
- the mixture was cycled two more times.
- the solution was then diluted 1:2 with PBS and a 20 ⁇ L aliquot of the solution was then removed, diluted in 2 mL of filtered (0.2 ⁇ m) PBS and the particle size determined using a Malvern 3000 HS Zetasizer.
- the formulation was then filtered sterilized.
- a 50 mL Steriflip filtration system was placed in an ice bucket, with a vacuum line attached and left for 1 hour to allow the device to equilibrate to the temperature of the ice.
- the poloxamer formulation was then filtered under vacuum, below the cloud point and then allowed to warm above the cloud point.
- a 20 ⁇ L aliquot of the solution was then removed, diluted in 2 mL of filtered (0.2 ⁇ m) PBS and the particle size determined.
- borosilicate vials (Wheaton) were then filled with 1 mL each of the formulation and the vials placed in a computer controlled Virtis Advantage freeze dryer. Initially the vials were cooled below ⁇ 40° C. for at least two hours and then the condenser was cooled to below ⁇ 40° C. and the vacuum reduced to below 300 mTorr. The first step in primary drying was to hold the vials at ⁇ 40° C. for one hour, under a vacuum of 120 mTorr. Then the temperature was raised to 20° C. over eight hours and the vacuum maintained at 120 mTorr. After eight hours the temperature and vacuum were maintained for a further one-hour.
- the secondary drying step involved raising the temperature to 30° C. over 30 minutes and holding this temperature for a further two hours, while maintaining a vacuum of 120 mTorr. Finally the temperature was reduced to 20° C. over 30 minutes; the vials were sealed with grey butyl rubber stoppers (WestDireet) under vacuum and the samples removed for analysis.
- microparticles for lyophilization in PBS were prepared by a similar procedure.
- the formulation contained final concentrations of 5 mg/ml DNA, 7.5 mg/mL CRL-1005, 0.3 mM BAK.
- the lyophilized particles in PBS were compared to the lyophilized particles in the 10% sucrose, 10 mM Sodium phosphate solution.
- Z average mean particle size and polydispersity were measured using a Malvern 3000 HS Zetasizer for both type of particles before and after lyophilization and the result are shown in Table 1.
- Sterile formulations containing DNA, CRL-1005 and other poloxamers with cationic ionic lipids, including but not limited to, benzalkonium chloride in 8.5% sucrose can be prepared as described herein. The mixture is then lyophilized, and when reconstituted, these formulations may be used in immunogenicity studies. The T-cell responses of animals injected with the formulations described above can be measured by IFN- ⁇ ELISpot assay and antigen-specific antibodies can be measured by ELISA. From the data, biologically active formulations with advantageous physical or pharmaceutical properties and/or formulations with enhanced biological activity can then be identified.
- Immunogenicity studies can be conducted using the experimental protocol as described below. Groups of nine, six- to eight-week old BALB/c mice (Harlan-Sprague-Dawley) will receive bilateral (50 ⁇ L/leg) intramuscular (rectus femoris) injections of naked plasmid DNA or formulated plasmid DNA.
- the plasmid (VR4700) to be injected in all mice encodes the influenza nucleoprotein (NP). All mice will be boosted on (approximately) days 21 and 49. Sera will be collected from NP-vaccinated mice after the third ( ⁇ day 60) vaccination, and NP-specific antibody responses will be measured by ELISA. Two weeks after the last immunization, splenocytes will be harvested from three mice/group/day for three sequential days, and antigen specific T-cell responses will be measured by IFN- ⁇ ELISpot assay.
- NP-specific antibodies produced in response to DNA vaccination will be evaluated by ELISA. Briefly, 96 well Costar hi-binding 1 ⁇ 2 well ELISA plates are coated with 2 ⁇ g/mL of recombinant NP protein (Imgenex, San Diego, Calif.) and blocked with 10% fetal bovine serum (FBS) in PBS. Wells are incubated with serial dilutions of each immune serum, and bound anti-NP antibody is detected by the sequential addition of alkaline phosphatase-labeled goat anti-mouse IgG-Fcy and the colorimetric substrate, p-nitrophenylphosphate. Conversion of the substrate is quantified at 405 nm.
- the end-point dilution titer is defined as the reciprocal dilution at which the optical density at 405 run is greater than twice that measured in wells containing assay buffer alone (i.e., the background value). An average absorbance of eight wells containing assay buffer is used to establish the background value. Wells incubated with a pool of sera from NP DNA-vaccinated mice serve as a positive control.
- T-cell responses to the DNA vaccines will be determined by quantifying the number of splenocytes secreting IFN- ⁇ in response to antigen-specific stimulation as measured by IFN- ⁇ ELISpot assay.
- Splenocyte cultures will be grown in RPMI-1640 medium containing 25 mM HEPES buffer and L-glutamine and supplemented with 10% (v/v) FBS, 55 ⁇ M ⁇ -mercaptoethanol, 100 U/mL of penicillin G sodium salt, and 100 ⁇ g/mL of streptomycin sulfate.
- ImmunoSpot plates (Cellular Technology Limited, Cleveland, Ohio) are coated with rat anti-mouse IFN- ⁇ monoclonal antibody (BD Biosciences, San Diego, Calif.), and blocked with RPMI-1640 medium.
- Splenocyte suspensions can be produced from individual vaccinated mice and seeded in ELISpot plates at 1 ⁇ 10 6 , 3 ⁇ 10 5 , or 1 ⁇ 10 5 cells/well in RPMI medium containing 1 ⁇ g/mL of the appropriate MHC class I-restricted peptide (M84, 297 AYAGLFTPL 305 , Imgenex, San Diego, Calif.; NP, 147 TYQRTRALV 155 , Sigma/Genosys, The Woods, Tex.) or 20 ⁇ g/mL of protein antigen with (CD8+ T cell ELISpot assay) or without (CD4+ T cell ELISpot assay) 1 U/mL of recombinant murine IL-2 (Roche, Indianapolis, Ind.
- Control wells contain 1 ⁇ 10 6 splenocytes incubated in medium with or without IL-2 only (no antigen). After a 20-hour incubation at 37° C., captured IFN- ⁇ is detected by the sequential addition of biotin-labeled rat anti-mouse IFN- ⁇ monoclonal antibody and avidin-horseradish peroxidase. Spots produced by the conversion of the colorimetric substrate, 3-amino-9-ethylcarbazole (AEC), are quantified by an ImmunoSpot reader (Cellular Technology Limited, Cleveland, Ohio).
Abstract
This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.
Description
- This application is a continuation application of U.S. application Ser. No. 10/725,009 filed Dec. 2, 2003, now pending; which claims the benefit under 35 USC § 119(e) to U.S. Application Ser. No. 60/435,273 filed Dec. 23, 2002, now abandoned. The disclosure of each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.
- 1. Field of the Invention
- This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.
- 2. Related Art
- The use of non-ionic block copolymers as adjuvants in polynucleotide based medicaments has been documented in the art. Polynucleotide complexes which comprise a polynucleotide, a block copolymer and a cationic surfactant have demonstrated enhanced in vivo immune response. In some cases, it is desirable or necessary to supply a suspension of these complexes in a dry powder form that can be reconstituted to an aqueous system just prior to use. One method of drying an aqueous medium is by lyophilization in which the medium is frozen and then the water is extracted by sublimation under vacuum. If the aqueous medium contains a suspension of microparticles, these microparticles tend to cluster during the initial freezing step of the lyophilization process due to the propagation of the crystallization front. Often, the microparticles become permanently aggregated and do not redisperse when reconstituted, creating a population with a very polydisperse size distribution.
- Methods for controlling aggregation during freeze-drying and reconstitution through the use of cryoprotectants and bulking agents or other excipients are known in the art and have been described for liposome formulations (See U.S. Pat. No. 5,817,334, hereby incorporated by reference in its entirety), microparticles (See U.S. Pat. No. 6,482,581, hereby incorporated by reference in its entirety) and nucleic acid-polycation compositions (See U.S. Pat. No. 6,251,599, hereby incorporated by reference in its entirety).
- Despite these advances, there exists a need for methods by which to freeze-dry and reconstitute compositions comprising a polynucleotide and a block copolymer that also contain a cationic surfactant, such that the same particle size and population polydispersity prior to freeze-drying are maintained following reconstitution. The present invention fulfills this need.
- In one aspect, the invention provides a method of preparing a lyophilized composition comprising mixing a block copolymer with a population of polynucleotide molecules, a cationic surfactant, and an amorphous cryoprotectant or a bulking agent or any combination thereof, at a temperature below the cloud point of the block copolymer to form a mixture. This mixture is then frozen and finally dried under vacuum. Upon reconstitution of this mixture, the particle size and population polydispersity are maintained.
- In a further embodiment, the composition comprising a polynucleotide, a block copolymer and a cationic surfactant are mixed at a temperature below the cloud point of the block copolymer, at a temperature of about −2° C. to about 8° C. In yet another aspect of the invention, prior to lyophilization, the mixture is cold filtered, thereby rendering it sterile. Suitably, this cold filtration step is performed at a temperature of about −2° C. to about 8° C. using a filter with a pore size of about 0.01 microns to about 2 microns.
- Block copolymers such as polyoxyethylene (POE)/polyoxypropylene (POP) are desired. An example of a useful block copolymer is Poloxamer CRL-1005. Suitable cationic surfactants for use in the present invention include benzalkonium chloride and (±)-N-(3-Acetoxypropyl)-N,N-dimethyl-2,3-bis(octyloxy)-1-propanaminium chloride (Pr-DoctRIe-OAc).
- Suitable amorphous cryoprotectants and crystalline bulking agents include the following sugars: sucrose, lactose, trehalose, maltose or glucose, wherein the solution comprises about 1% to about 20% (w/v) sugar. A suitable embodiment of the invention contains about 10% sucrose. The composition may also optionally comprise a pH stabilizing buffer.
- The present invention also encompasses the polynucleotide/block copolymer/cationic surfactant microparticles produced by the lyophilization processes described herein.
-
FIG. 1A andFIG. 1B are graphs plotting the Z average mean particle size and polydispersity of reconstituted lyophilized microparticles produced by the method described in Example 1. -
FIG. 2 contains the structures of the following cationic lipids: Benzalkonium chloride (BAK C12), (±)-N-(Benzyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (Bn-DHxRIE), (±)-N-(2-Acetoxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OAc), (±)-N-(2-Benzoyloxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanraminium bromide (DHxRIE-OBz) and (±)-N-(3-Acetoxypropyl)-N,N-dimethyl-2,3-bis(octyloxy)-1-propanaminium chloride (Pr-DOctRIE-OAc). - As used herein, “PBS” refers to—phosphate buffered saline—.
- As used herein, “BAK” refers to—benzalkonium chloride—.
- As used herein, “BEC” refers to—benzethonium chloride—.
- As used herein, “CPC” refers to—cetylpyridinium chloride—.
- As used herein, “CTAC” refers to—cetyl trimethyl-ammonium chloride—.
- As used herein, “PS-80” refers to—polysorbate 80—.
- As used herein, the term “cloud point” refers to the point in a temperature shift, or other titration, at which a clear solution becomes cloudy, i.e., when a component dissolved in a solution begins to precipitate out of solution.
- As used herein, the words “particle” and “microparticle” are interchangeable.
- As used herein, the words “mixture” and “solution” are interchangeable.
- As used herein, the term “adjuvant” is any substance or combination of substances which nonspecifically enhances the immune response to an antigen; and also relates to any substance which enhances the immune response directly related to delivery of a polynucleotide within a vertebrate or mammalian host, such as a human or non-human mammalian host, such that administration of the adjuvant in combination with the polynucleotide results in an increased in vivo immune response to expression of the intended antigen or antigens encoded by the polynucleotide. Included in this definition are substances which may act as facilitators of gene delivery, thereby increasing the amount of plasmid DNA delivered to cells that can express the intended antigen. Substances which may enhance delivery of plasmid DNA would include those which do not substantially interact with the plasmid DNA in the formulation and substances which do interact with the plasmid DNA, forming tightly bound or weakly bound complexes between the adjuvant and the plasmid DNA, either in vitro or in vivo.
- As used herein, the term “polynucleotide” is a nucleic acid molecule which contains essential regulatory elements such that upon introduction into a living, vertebrate cell, the nucleic acid molecule is able to direct the cellular machinery to produce translation products encoded by the genes comprising the nucleic acid molecule.
- As used herein, the term “polynucleotide medicament” is used to indicate polynucleotide-based compositions, including compositions which comprise the poloxamers and cationic surfactants disclosed herein, useful as a vehicle to deliver a transgene of interest to a vertebrate host, such as a human or non-human mammalian host, or to provide or promote detectable and/or therapeutic levels of expression of the transgene, and/or to generate or promote an immune response to the expression product of the transgene.
- As used herein, the term “vector” refers to a vehicle by which DNA fragments, most likely comprising a transgene or portion thereof which expresses an antigen or antigenic epitope, can be introduced into a host organism or host tissue. There are various types of vectors which include but are not limited to recombinant vectors, including DNA plasmid vectors, recombinant viral vectors such as adenovirus vectors, retrovirus vectors and adeno-associated virus vectors, as well as bacteriophage vectors and cosmid vectors.
- The term “gene” or “transgene” refers to a segment of a nucleic acid molecule which encodes a discrete protein or a portion thereof, such as a portion of the full-length protein which will induce an appropriate immune response within the host.
- As used herein, the term “amorphous cryoprotectant” refers to a compound which, when included in the formulations of the present invention during freezing or lyophilization under given conditions, does not form crystals. It is specifically intended that compounds that are known to form crystals under certain lyophilization conditions but not under others are included within the term “amorphous cryoprotectant,” so long as they remain amorphous under the specific freezing or lyophilization conditions to which they are subjected. The term “cryoprotectant” may be used interchangeably with the term “amorphous cryoprotectant” herein.
- As used herein, “crystalline bulking agent” refers to a compound which, when included in the formulations of the present invention during freezing or lyophilization under given conditions, forms crystals. It is specifically intended that compounds that are known to form crystals under certain lyophilization conditions but not under others are included within the term “crystalline bulking agent,” so long as they crystallize under the specific freezing or lyophilization conditions to which they are subjected. The term “bulking agent” may be used interchangeably with the term “crystalline bulking agent” herein.
- As used herein, “lyophilization” is a means of drying, achieved by freezing a wet substance at a temperature from about −172° C. to about −2° C. followed by rapid dehydration by sublimation under a vacuum level down to the lower level of a diffusion pump. A useful pressure range is from about 0.1 mTorr to about 0.5 Torr. The term “freeze-drying” may be used interchangeably with the term “lyophilization” herein.
- Amorphous cryoprotectants, crystalline bulking agents, and methods of determining the same are known and available in the art. The following articles, incorporated herein by reference, provide a basic teaching in this regard: Osterberg et al., Pharm Res 14(7):892-898 (1997); Oliyai et al., Pharm Res 11(6):901-908 (1994); Corveleyn et al., Pharm Res 13(1):146-150 (1996); Kim et al., J. Pharm Sciences 87(8):931-935 (1998); Martini et al., PDA J. Pharm Sci Tech 51(2):62-67 (1997); Martini et al., STP Pharma Sci. 7(5):377-381 (1997); and Orizio et al., Boll. Chim. Farm. 132(9):368-374 (1993).
- The present invention relates to novel methods for lyophilizing a formulation suitable for use in polynucleotide based medicaments. The methods result in formulations comprising polynucleotide molecules, block copolymer, and a cationic surfactant that upon reconstitution maintain the same particle size and polydispersity prior to freeze-drying.
- The method of the present invention comprises mixing: (i) a cationic surfactant; (ii) a block copolymer; and (iii) a polynucleotide; at a temperature below the cloud point of said block copolymer to form a mixture. The order in which components of the mixture are added may vary. A suitable order in which ingredients of the mixture may be added include, but is not limited to, (i) polynucleotide; (ii) block copolymer; and (iii) cationic surfactant. Alternatively, the order of addition can also include: (i) cationic surfactant; (ii) block copolymer; and (iii) polynucleotide. Stirring of the mixture can occur once all components have been added, concurrently while components are being added, or in between the addition of components.
- The block copolymers useful in the polynucleotide based medicaments described herein are block copolymers which form microparticles at room temperature (above the block copolymer cloud point) and may associate with a population of nucleic acid molecules, such as a population of plasmid DNA molecules, with and without the addition of cationic surfactants. The nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA) as well as a ribonucleic acid molecule (RNA). In regard to the block copolymer, a suitable group of copolymers used in the methods of the present invention include non-ionic block copolymers which comprise blocks of polyoxyethylene (POE) and polyoxypropylene (POP).
- While the invention contemplates the use of any such block copolymer which promotes generation of a particle size and surface charge as described herein, suitable non-ionic block copolymers include polyoxyethylene (POE)/polyoxypropylene (POP) block copolymers, especially higher molecular weight POE-POP-POE block copolymers. These compounds are described in U.S. Reissue Pat. No. 36,665, U.S. Pat. No. 5,567,859, U.S. Pat. No. 5,691,387, U.S. Pat. No. 5,696,298 and U.S. Pat. No. 5,990,241, and Published International Patent Application WO 96/04392, all of which are hereby incorporated by reference.
- Briefly, these non-ionic block copolymers have the following general formula: HO(C2H4O)x(C3H6O)y(C2H4O)xH wherein (y) represents a number such that the molecular weight of the hydrophobic POP portion (C3H6O) is up to approximately 20,000 daltons and wherein (x) represents a number such that the percentage of hydrophilic POE portion (C2H4O) is between approximately 1% and 50% by weight.
- A suitable POE-POP-POE block copolymer that can be used in the invention has the following formula HO(C2H4O)x(C3H6O)y(C2H4O)xH wherein (y) represents a number such that the molecular Weight of the hydrophobe (C3H6O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is between approximately 3% and 35%.
- Another suitable POE-POP-POE block copolymer that can be used in the invention has the following formula: HO(C2HO)x(C3H6O)y(C2H4O)xH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is between approximately 3% and 10%.
- A typical POE/POP block copolymer utilized herein will comprise the structure of POE-POP-POE, as reviewed in Newman et al. Critical Reviews in Therapeutic Drug Carrier Systems 15 (2): 89-142 (1998). A suitable block copolymer for use in the methods of the present invention is a POE-POP-POE block copolymer with a central POP block having a molecular weight in a range from under 1000 daltons up to approximately 20,000 daltons and flanking POE blocks which comprise up to about 50% of the total molecular weight of the copolymer. Block copolymers such as these, which are much larger than earlier disclosed Pluronic-based POE/POP block copolymers, are described in detail in U.S. Reissue Pat. No. 36,655. A representative POE-POP-POE block copolymer utilized to exemplify DNA formulations of the present invention is disclosed in Published International Patent Application No. WO 96/04392, is also described at length in Newman et al. (Id.), and is referred to as CRL-1005 (CytRx Corp).
- CRL-1005 is another suitable surface-active copolymer that can be used in the invention and has the following formula: HO(C2H4O)x(C3H6O)y(C2H4O)xH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is approximately 12,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is approximately 5%. In the case of CRL-1005, (x) is about 7, ±1 and (y) is approximately 12,000 Daltons, with about 207 units, ±7.
- Although there is evidence to suggest that the association of plasmid DNA to the CRL-1005 particles leads to an improved immune response, the mechanism by which the immune response is enhanced is at present unclear. While not being bound by theory in any way, it is possible that DNA associated to CRL-1005 particles may be more readily taken up and expressed by cells. It is also possible that the negative surface charge of the CRL-1005 particles, produced by the association of plasmid DNA to CRL-1005/BAK particles, may be important for enhancing the adjuvant properties of CRL-1005. The current invention does not distinguish between these two possible mechanisms of enhancing the immune response.
- The measurement of surface charge (zeta potential) and the amount of DNA associated with CRL-1005 particles are consistent with a model for the interaction of plasmid DNA/the block copolymer (CRL-1005) and the cationic surfactant (for example, BAK). The model suggests that BAK associating with particles of CRL-1005, through hydrophobic interactions, results in a reduction of the CRL-1005 particle size and in the formation of positively charged CRL-1005 particles. Association of the polynucleotide (plasmid DNA) is believed to occur through electrostatic interactions between the positively charged headgroup of the cationic surfactant (BAK) and the DNA phosphate groups, while the hydrophobic tail of the cationic surfactant is embedded within the block copolymer (CRL-1005) particle.
- Published International Patent Application WO 02/00844 discloses that the generation of physically distinct particles comprising the block co-polymer CRL-1005, a cationic surfactant and DNA, further promotes the association of plasmid DNA to the block copolymer as compared to the block co-polymer and DNA alone. The particles containing all three components also resulted in a marked enhancement of a cellular immune response.
- An alternative surface-active copolymer that can be used in the invention has the following formula: HO(C2H4O)x(C3H6O)y(C2H4O)xH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is approximately 9,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is approximately 3-5%.
- Another suitable surface-active copolymer that can be used in the invention has the following formula: HO(C2H4O)x(C3H6O)y(C2H4O)xH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is approximately 9,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is approximately 3%.
- In yet another alternative embodiment the present invention relates to a method for producing a lyophilized formulation suitable for use in polynucleotide based medicaments comprising a block copolymer which is Poloxamer CRL-1005.
- Another suitable group of block copolymers for use in the present invention include “reverse” block copolymers wherein the hydrophobic portions of the molecule (C3H6O) and the hydrophilic portions (C2H4O) have been reversed such that the polymer has the formula: HO(C3H6O)y(C2H4O)x(C3H6O)yH wherein (y) represents a number such that the molecular weight of the hydrophobic POP portion (C3H6O) is up to approximately 20,000 daltons and wherein (x) represents a number such that the percentage of hydrophilic POE portion (C2H4O) is between approximately 1% and 50% by weight. These “reverse” block copolymers have the structure POP-POE-POP and are described in U.S. Pat. Nos. 5,656,611 and 6,359,054.
- A suitable POP-POE-POP block copolymer that can be used in the invention has the following formula: HO(C3H6O)y(C2H4O)x(C3H6O)yH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is between approximately 3% and 35%.
- Another suitable POP-POE-POP block copolymer that can be used in the invention has the following formula: HO(C3H6O)y(C2H4O)x(C3H6O)yH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is between approximately 9,000 Daltons and 15,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is between approximately 3% and 10%.
- Another suitable surface-active copolymer that can be used in the invention and has the following formula: HO(C3H6O)y(C2H4O)x(C3H6O)yH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is approximately 12,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is approximately 5%.
- An alternative surface-active copolymer that can be used in the invention has the following formula: HO(C3H6O)y(C2H4O)x(C3H6O)yH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is approximately 9,000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is approximately 3-5%.
- Another suitable surface-active copolymer that can be used in the invention has the following formula: HO(C3H6O)y(C2H4O)x(C3H6O)yH wherein (y) represents a number such that the molecular weight of the hydrophobe (C3H6O) is approximately 9000 Daltons and (x) represents a number such that the percentage of hydrophile (C2H4O) is approximately 3%.
- The block copolymers for use in the invention are amphipathic compounds with inverse solubility characteristics in aqueous media. Below their cloud points (1-20° C.), these copolymers are water-soluble and form clear solutions that can be filter sterilized. The solution process involves the formation of hydrogen bonds between oxygen atoms and hydroxyl groups in the copolymer and water molecules. When a solution of copolymer is warmed and passes through its cloud point, the increased thermal motion is sufficient to break the hydrogen bonds and as the copolymer comes out of solution, they self-assemble into microparticles (See Todd, C. W., et al.
Vaccine 15. 564-570 (1997) and Todd, C. W., et al. Dev. Biol. Stand. 92: 343-353 (1997)). The process is reversible. - Any type of polynucleotide can be incorporated into the method of the current invention. For example plasmid DNA, genomic DNA, cDNA, DNA fragments and RNA. Certain formulations of the present invention include a cocktail of plasmids. Various plasmids desired in a cocktail are combined together in PBS or other diluent prior to addition to the other ingredients. There is no upper limit to the number of different types of plasmids which can be used in the methods of the present invention. Furthermore, plasmids may be present in a cocktail at equal proportions, or the ratios may be adjusted based on, for example, relative expression levels of the antigens or the relative immunogenicity of the encoded antigens. Thus, various plasmids in the cocktail may be present in equal proportion, or 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times as much of one plasmid may be included relative to other plasmids in the cocktail.
- The polynucleotide formulations produced by the methods of the present invention also comprise a cationic surfactant. It will be known to one of skill in the art that numerous cationic surfactants may be a candidate for use in these formulations. Therefore, the invention contemplates use of any cationic surfactant which, along with a block copolymer, and a polynucleotide promotes generation of a particle size and surface charge as described herein. Cationic surfactants which may be used include, but are not limited to, benzalkonium chloride (BAK), benzethonium chloride, cetramide (which contains tetradecyltrimethylammonium bromide and possibly small amounts of dedecyltrimethylammonium bromide and hexadecyltrimethyl ammonium bromide), cetylpyridinium chloride (CPC) and cetyl trimethylammonium chloride (CTAC), primary amines, secondary amines, tertiary amines, including but not limited to N,N′,N′-polyoxyethylene (10)-N-tallow-1,3-diaminopropane, other quaternary amine salts, including but not limited to dodecyltrimethylammonium bromide, hexadecyltrimethyl-ammonium bromide, mixed alkyl-trimethyl-ammonium bromide, benzyldimethyldodecylammonium chloride, benzyldimethylhexadecyl-ammonium chloride, benzyltrimethylammonium methoxide, cetyldimethylethylammonium bromide, dimethyldioctadecyl ammonium bromide (DDAB), methylbenzethonium chloride, decamethonium chloride, methyl mixed trialkyl ammonium chloride, methyl trioctylammonium chloride), N,N-dimethyl-N-[2 (2-methyl-4-(1,1,3,3tetramethylbutyl)-phenoxy]-ethoxy) ethyl]-benzenemethanaminium chloride (DEBDA), dialkyldimethylammonium salts, -[1-(2,3-dioleyloxy)-propyl]-N,N,N, trimethylammonium chloride, 1,2-diacyl-3-(trimethylammonio) propane (acyl group=dimyristoyl, dipalmitoyl, distearoyl dioleoyl), 1,2-diacyl-3 (dimethylammonio) propane (acyl group=dimyristoyl, dipalmitoyl, distearoyl, dioleoyl), 1,2-dioleoyl-3-(4′-trimethyl-ammonio) butanoyl-sn-glycerol, 1,2-dioleoyl3-succinyl-sn-glycerol choline ester, cholesteryl (4′-trimethylammonio) butanoate), N-alkyl pyridinium salts (e.g. cetylpyridinium bromide and cetylpyridinium chloride), N-alkylpiperidinium salts, dicationic bolaform electrolytes (C12Me6; C12Bu6), dialkylglycetylphosphorylcholine, lysolecithin, L-adioleoyl phosphatidylethanolamine, cholesterol hemisuccinate choline ester, lipopolyamines, including but not limited to dioctadecylamidoglycylspermine (DOGS), dipalmitoyl phosphatidylethanol-amidospermine (DPPES), lipopoly-L (or D)-lysine (LPLL, LPDL), poly (L (or D)-lysine conjugated to N-glutarylphosphatidylethanolamine, didodecyl glutamate ester with pendant amino group (C12GluPhCnN+), ditetradecyl glutamate ester with pendant amino group (C14GluCnN+), cationic derivatives of cholesterol, including but not limited to cholesteryl-3β-oxysuccinamidoethylenetrimethylammonium salt, cholesteryl-3β-oxysuccinamidoethylenedimethylamine, cholesteryl-3β-carboxyamidoethylenetrimethylammonium salt, cholesteryl-3β-carboxyamidoethylenedimethylamine, and 3β-[N-(N′,N′-dimethylaminoetanecarbomoyl) cholesterol] (DC-Chol).
- Other examples of cationic surfactants for use in the invention are selected from the group of cationic lipids including N-(3-aminopropyl)-N,N-(bis-(2-tetradecyloxyethyl))-N-methyl-ammonium bromide (PA-DEMO), N-(3-aminopropyl)-N,N-(bis-(2-dodecyloxyethyl))-N-methyl-ammonium bromide (PA-DELO), N,N,N-tris-(2-dodecyloxy)ethyl-N-(3-amino)propyl-ammonium bromide (PA-TELO), and N1-(3-aminopropyl)((2-dodecyloxy)ethyl)-N2-(2-dodecyloxy)ethyl-1-piperazinaminium bromide (GA-LOE-BP), DL-1,2-dioleoyl-3-dimethylaminopropyl-β-hydroxyethylammonium (DORI diester), and 1-O-oleyl-2-oleoyl-3-dimethylaminopropyl-β-hydroxyethylammonium (DORI ester/ether).
- Additional suitable, but non-limiting cationic lipids for use in certain embodiments of the present invention include DMRIE ((±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide), GAP-DMORIE ((±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradeceneyloxy)-1-propanaminium bromide), and GAP-DLRIE ((±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-dodecyloxy)-1-propanaminium bromide).
- Other cationic lipids for use in the present invention include the compounds described in U.S. Pat. Nos. 5,264,618, 5,459,127 and 5,994,317. Non-limiting examples of these cationic lipids include (±)-N,N-dimethyl-N-[2-(sperminecarboxamido)ethyl]-2,3-bis(dioleyloxy)-1-pr opaniminium pentahydrochloride (DOSPA), (±)-N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propaniminium bromide (β-aminoethyl-DMRIE or βAE-DMRIE) and (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propaniminium bromide (GAP-DLRIE).
- Other examples of DMRIE-derived cationic lipids that are useful in the present invention include (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-decyloxy)-1-propanaminium bromide (GAP-DDRIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-tetradecyloxy)-1-propanaminium bromide (GAP-DMRIE), (±)-N-((N″-methyl)-N′-ureyl)propyl-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (GMU-DMRIE), (±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (DLRIE), and (±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis-([Z]-9-octadecenyloxy)propyl-1-propaniminium bromide (HP-DORIE).
- In a suitable aspect of the present invention, the cationic surfactant is selected from the group consisting of benzalkonium chloride, benzethonium chloride, cetramide, cetylpyridinium chloride and cetyl trimethylammonium-chloride. Benzalkonium chloride is available commercially and is known to exist as a mixture of alkylbenzyldimethylammonium chlorides of the general formula: [C6H5CH2N(CH3)2R] C1, where R represents a mixture of alkyls, including all or some of the group beginning with n-C8H17 through n-C16H33. The average MW of BAK is 360 (see Handbook of Pharmaceutical Excipients, Ed. Wade and Weller, 1994, 2nd Ed. at page 27-29). Benzethonium chloride is N,N-dimethyl-N-[2-[2-[4-(1,1,3,3tetramethylbutyl)phenoxy]ethoxy]ethyl]benzene-methanaminium chloride (C27H42CINO2), which has a molecular weight of 448.10 (Handbook of Pharmaceutical Excipients at page 30-31). Cetramide consists mainly of trimethyltetradecylammonium bromide (C17H38BrN), which may contain smaller amounts of dodecyltrimethyl-ammonium bromide (C15H34BrN) and hexadecyltrimethylammonium bromide (C19H42BrN), and has a molecular weight of 336.40 (Handbook of Pharmaceutical Excipients at page 96-98).
- In another suitable aspect of the present invention, the cationic surfactant for use in the methods of the current invention is selected from the group consisting of (±)-N-(Benzyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (Bn-DHxRIE), (±)-N-(2-Acetoxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OAc), (±)-N-(2-Benzoyloxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OBz) and (±)-N-(3-Acetoxypropyl)-N,N-dimethyl-2,3-bis(octyloxy)-1-propanaminium chloride (Pr-DOctRIE-OAc). These lipids are disclosed in U.S. Provisional Application No. 60/435,303. In another suitable aspect of the present invention, the cationic surfactant is Pr-DOctRIE-OAc.
- Auxiliary agents for use in compositions of the present invention include, but are not limited to, non-ionic detergents and surfactants IGEPAL CA 630® CA 630, NONIDET NP-40, Nonidet® P40, Tween-20®, Tween-80®, Triton X-100™, and Triton X-114™; the anionic detergent sodium dodecyl sulfate (SDS); the sugar stachyose; the condensing agent DMSO; and the chelator/DNAse inhibitor EDTA. In certain specific embodiments, the auxiliary agent is DMSO, Nonidet P40®. See, e.g., U.S. Patent Application Publication 20020019358, published Feb. 14, 2002, which is incorporated herein by reference in its entirety.
- The polynucleotide formulations produced by the methods of the present invention may also optionally include a non-ionic surfactant, such as polysorbate-80, which may be a useful excipient to control particle aggregation in the presence of the polynucleotide. Additional non-ionic surfactants are known in the art and may be used to practice this portion of the invention. These additional non-ionic surfactants include, but are not limited to, other polysorbates, -Alkylphenyl polyoxyethylene ether, n-alkyl polyoxyethylene ethers (e.g., Tritons™), sorbitan esters (e.g., Spans™), polyglycol ether surfactants (Tergitol™), polyoxyethylenesorbitan (e.g., Tweens™), poly-oxyethylated glycol monoethers (e.g., Brij™, polyoxylethylene 9 lauryl ether, polyoxyethylene 10 ether, polyoxylethylene 10 tridecyl ether), lubrol, perfluoroalkyl polyoxylated amides, N,N-bis[3D-gluconamidopropyl]cholamide, decanoyl-N-methylglucamide, -decyl β-D-glucopyranozide, n-decyl β-D-glucopyranozide, n-decyl β-D-maltopyanozide, ndodecyl β-D-glucopyranozide, n-undecyl β-D-glucopyranozide, n-heptyl β-D-glucopyranozide, n-heptyl β-D-thioglucopyranozide, n-hexyl β-D-glucopyranozide, n-nonanoyl β-glucopyranozide 1-monooleyl-rac-glycerol, nonanoyl-N-methylglucamide, -dodecyl β-D-maltoside, N,N bis[3-gluconamidepropyl]deoxycholamide, diethylene glycol monopentyl ether, digitonin, hepanoyl-N-methylglucamide, octanoyl-N-methylglucamide, n-octyl β-D-glucopyranozide, n-octyl β-D-glucopyranozide, n-octyl β-D-thiogalactopyranozide, n-octyl β-D-thioglucopyranozide.
- The present invention relates to methods for lyophilizing a formulation suitable for use in polynucleotide based medicaments such that upon reconstitution, the particle size and population polydispersity of the microparticles remain unchanged. The methods result in the generation of microparticles (at temperatures above the cloud point of CRL-1005, or another representative block copolymer) which comprise a block copolymer and cationic surfactant in contact with polynucleotide molecules. The components which will eventually comprise the microparticles are mixed with an amorphous cryoprotectant or a crystalline bulking agent by stirring at temperature below the cloud point of the block copolymer. Additionally, the mixture may also comprise a pH stabilizing buffer. Each component of this mixture must be thoroughly co-dissolved at a temperature below the cloud point of the polymer. This solution can also be sterilized via cold filtration and aliquoted into sterile vials prior to lyophilization. Prior to administration to a patient by injection, or any other means, the freeze-dried formulation can be reconstituted and the vial can be brought to room temperature or to a temperature above the cloud point of the block copolymer, wherein microparticle formation will occur during the warming process. It is the discovery of the current inventors that microparticle reconstitution results in particles with a particle size and a population polydispersity that remains unchanged during the freeze-drying process. This is further illustrated in Examples 1 and 2. Table 1 indicates the mean average diameter of microparticles composed of polynucleotide, poloxamer CRL-1005 and BAK co-dissolved in solutions of both PBS and 10% sucrose/10 mM sodium phosphate. The microparticles prepared in PBS have a much larger polydispersity following reconstitution than prior to freeze-drying indicating a broad size range of particles. In contrast, the microparticles co-dissolved in 10% sucrose/10 mM sodium phosphate demonstrate virtually the same polydispersity before lyophilization and after reconstitution, indicating a narrow size distribution.
FIGS. 1A and 1B demonstrate that particle size and polydispersity remain unchanged after 6 hours at room temperature following reconstitution. - The lyophilized composition of the present invention may be reconstituted in any aqueous solution which produces a stable, mono-dispersed solution suitable for administration. Such aqueous solutions include, but are not limited to: sterile water, PBS or saline.
- Upon review of this specification, the artisan will be able to mix and match various block copolymers, cationic surfactants, excipients, as well as utilize various concentrations of these components. The artisan will be able to measure in vitro structural characteristics of the formulation, as shown herein, which may be instructive in preparing such components for in vivo administration.
- In suitable embodiments of the present invention a polynucleotide is mixed with the poloxamer CRL-1005, BAK (
Benzalkonium chloride 50% solution, available from Ruger Chemical Co. Inc.) and an amorphous cryoprotectant or crystalline bulking agent. Additionally, the mixture may also comprise a pH stabilizing buffer. Suitable final concentrations of each component of the formulae are described in the examples, but for any of these methods, the concentrations of each component may be varied by basic stoichiometric calculations known by those of ordinary skill in the art to make a final solution having the desired concentrations. - In the method of the current invention, the concentration of the block copolymer is adjusted depending on, for example, transfection efficiency, expression efficiency, or immunogenicity. In suitable embodiments, the final concentration of the block copolymer is between about 1 mg/mL to about 75 mg/mL. Alternatively the final concentration of the block copolymer is between about 3 mg/mL to about 50 mg/mL, about 5 mg/mL to about 40 mg/mL, about 6 mg/mL to about 30 mg/mL. For example, about 6 mg/mL, about 6.5 mg/mL about 7 mg/mL, about 7.5 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, or about 30 mg/mL of the block copolymer.
- In another suitable embodiment of the method of the current invention, the concentration of the poloxamer CRL-1005 is adjusted depending on, for example, transfection efficiency, expression efficiency, or immunogenicity. In suitable embodiments, the final concentration of the poloxamer CRL-1005 is between about 1 mg/mL to about 75 mg/mL. Alternatively the final concentration of the poloxamer CRL-1005 is between about 3 mg/mL to about 50 mg/mL, about 5 mg/mL to about 40 mg/mL, about 6 mg/mL to about 30 mg/mL. For example, about 6 mg/mL, about 6.5 mg/mL about 7 mg/mL, about 7.5 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, or about 30 mg/mL of CRL-1005. Similarly the concentration of DNA in the methods of the current invention is adjusted depending on many factors, including the amount of a formulation to be delivered, the age and weight of the subject, the delivery method and route and the immunogenicity of the antigen being delivered. In an alternative embodiment, the final concentration of DNA is from about 1 mg/mL to about 30 mg/mL of plasmid (or other polynucleotide). Alternatively, a formulation of the present invention may have a final concentration of DNA from about 0.1 mg/mL to about 20 mg/mL, or about 1 mg/mL to about 10 mg/mL. For example, the final DNA concentration may be about 1 mg/mL, about 2 mg/mL, about 2.5 mg/mL, about 3 mg/mL, about 3.5 mg/mL, about 4 mg/mL, about 4.5 mg/mL, about 5 mg/mL, about 5.5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, or about 20 mg/mL.
- Additionally, the concentration of the cationic surfactant may be adjusted depending on, for example, a desired particle size and improved stability. Indeed, in certain embodiments, the methods of the present invention include CRL-1005 and DNA, but are free of cationic surfactant. In general, cationic surfactant-containing formulations of the present invention are adjusted to have a final concentration of cationic surfactant from about 0.01 mM to about 5 mM. Suitably, a formulation of the present invention may have a final cationic surfactant concentration of about 0.06 mM to about 1.2 mM, or about 0.1 mM to about 1 mM, or about 0.2 mM to about 0.7 mM. For example, a formulation of the present invention may have a final cationic surfactant concentration of about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, or about 0.7 mM.
- Additionally, the concentration of BAK may be adjusted depending on, for example, a desired particle size and improved stability. Indeed, in certain embodiments, the methods of the present invention include CRL-1005 and DNA, but are free of BAK. In general BAK-containing formulations of the present invention are adjusted to have a final concentration of BAK from about 0.01 mM to about 5 mM. Alternatively, a formulation of the present invention may have a final BAK concentration of about 0.06 mM to about 1.2 mM, or about 0.1 mM to about 1 mM, or about 0.2 mM to about 0.7 mM. For example, a formulation of the present invention may have a final BAK concentration of about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, or about 0.7 mM.
- The total volume of the formulations produced by the methods of the current invention may be scaled up or down, by choosing apparatus of proportional size. Finally, in carrying out any of the methods described below, the three components of the formulation, BAK, CRL-1005, and plasmid DNA, may be added in any order.
- The polynucleotide based medicaments produced by the methods of the present invention may be formulated in any pharmaceutically effective formulation for host administration. It will be useful to utilize pharmaceutically acceptable formulations which also provide long-term stability of the polynucleotide based medicaments of the present invention. During storage as a pharmaceutical entity, DNA plasmids undergo a physiochemical change in which the supercoiled plasmid converts to the open circular and linear form. A variety of storage conditions (low pH, high temperature, low ionic strength) can accelerate this process. Therefore, the removal and/or chelation of trace metal ions (with succinic or malic acid, or with chelators containing multiple phosphate ligands, or with chelating agents such as EDTA) from the DNA plasmid solution, from the formulation buffers or from the vials and closures, stabilizes the DNA plasmid from this degradation pathway during storage.
- In one embodiment of the invention, the particles formed by the current method are from about 100 nm to about 2000 nm in diameter. The non-ionic block copolymer particle in the presence of the cationic surfactant will have a positive surface charge whereas the polymer particle in the presence of cationic surfactant and DNA should have a surface charge significantly more negative than the polymer particle alone. The exemplified microparticles described in the Example sections range from about 200-600 nm in diameter with a slightly positive zeta potential measurement in the presence of BAK but without addition of the polynucleotide (about 2.5 mV for CRL-1005 and 0.71 mM BAK) and a negative zeta potential when the polynucleotide (at 5 mg/mL) is present (about −46.6 mV for CRL-1005 and 0.71 mM BAK and 5 mg/mL plasmid DNA). While these values are instructive, they are by no way limiting.
- The addition of a cationic surfactant changes the configuration or structural integrity of the particle, which in turn increases the ability of the altered structure to better interact with polynucleotide molecules. Therefore, while ranges of surface charge and size measurements of various particles may be instructive, they are not necessarily limiting. One of ordinary skill in the art can adjust concentrations of one type of block copolymer and one type of cationic surfactant to form distinct microparticles, wherein the microparticles are ultimately characterized by an increased ability to associate with a specific population of polynucleotide molecules.
- The formulation produced by the methods of the current invention may be aliquoted into a suitable container for storage. Suitable containers include, but are not limited to, glass vials, glass bottles, syringes, sterilizable plastic bags, polyethylene tubes, vials or bottles, and polypropylene tubes, vials or bottles and any other container suitable for manufacturer bulk use or in the preparation of a kit comprising the polynucleotide based medicaments of the invention.
- The method of the present invention also relates to mixing a cationic surfactant, a block copolymer, a population of polynucleotide molecules and an amorphous cryoprotectant or a crystalline bulking agent and any combination thereof at a temperature above the cloud point of said block copolymer. The cloud point is dependent upon the block copolymer used in the mixture of the current invention. However, the suitable cloud point can range from about 1° C. to about 20° C. When CRL-1005 is the block copolymer, the temperature at which the mixture of the current invention is mixed can range from about 8° C. to about 35° C.
- To this end, the present invention also relates to a polynucleotide based medicament formulation which first comprises a polynucleotide, an adjuvant component comprising a block copolymer, a cationic surfactant and an amorphous cryoprotectant or a crystalline bulking agent, as described within this specification, and secondly comprising a non-ionic surfactant, such as polysorbate-80 or other excipients, including but not limited to excipients known in the art such as glycerol or propylene glycol, or a non-ionic surfactant listed herein.
- In a suitable embodiment of this invention, a formulation comprising a polynucleotide, a block copolymer, a cationic surfactant and an amorphous cryoprotectant or a crystalline bulking agent are co-solubilized at a temperature below the cloud point of the block copolymer. The presence of this cryoprotectant or bulking agent provides stability to the polynucleotide formulation during the freeze-drying process and subsequent reconstitution. By “stability,” it is meant that average size and size distribution are not affected, i.e. that little or no fusion or aggregation is observed upon reconstitution.
- Amorphous cryoprotectants which are suitable for use herein include inter alia, mono, di, or oligosaccharides, polyols, and proteins such as albumin; disaccharides such as sucrose and lactose; monosaccharides such as fructose, galactose and glucose; poly alcohols such as glycerol and sorbitol; and hydrophilic polymers such as polyethylene glycol.
- The amorphous cryoprotectant is suitably added to the formulations of the present invention before freezing, in which case it can also serve as a bulking agent. However, as a hydrophilic component, it may also provide for enhanced liquid stability.
- With regard to crystalline bulking agents, such agents are often used in the preparation of pharmaceutical compositions to provide the necessary bulk upon lyophilization. Many types of crystalline bulking agents are known in the art. (See, Martini et al. PDA J. Pharm Sci Tech 51(2):62-61, 1997).
- Exemplary crystalline bulking agents include D-mannitol, trehalose, and dextran. As the aforementioned are exemplary only, one skilled in the art would recognize that any compound which, when included in the formulations of the present invention during freezing or lyophilization under given conditions, forms crystals, would be considered a suitable crystalline bulking agent. Within the context of the present invention a crystalline bulking agent is generally defined as a compound which can exist in a crystalline form and whose glass transition point (Tg) is below the temperature at which it is being freeze-dried. For example, a conventional freeze-dryer operates at a shelf-temperature from between about −10° C. to about −50° C. Therefore, in one embodiment, a crystalline bulking agent has a Tg below about −50° C.
- In a suitable embodiment, the solution comprises about 1% to about 20% (w/v) of the amorphous cryoprotectant or crystalline bulking agent. In a suitable embodiment, the solution contains about 3% to about 17%, about 5% to about 15% or about 8% to about 12% (w/v) amorphous cryoprotectant or crystalline bulking agent. For example about 8%, about 9%, about 10%, about 11%, or about 12% (w/v) amorphous cryoprotectant or crystalline bulking agent.
- Suitable for use in the present invention are cryoprotectants and bulking agents from the group consisting of, but not limited to the following sugars: sucrose, lactose, trehalose, maltose or glucose. In a suitable embodiment, the solution comprises about 1% to about 20% (w/v) sugar. In a suitable embodiment, the solution contains about 3% to about 17%, about 5% to about 15% or about 8% to about 12% (w/v) sugar. For example about 8%, about 9%, about 10%, about 11%, or about 12% (w/v) sugar.
- In another suitable embodiment the solution contains about 1% to about 20% (w/v) sucrose. In a suitable embodiment, the solution contains about 3% to about 17%, about 5% to about 15% or about 8% to about 12% (w/v) sucrose. For example about 8%, about 9%, about 10%, about 11%, or about 12% (w/v) sucrose. In yet another suitable embodiment, the solution contains about 10% (w/v) sucrose.
- In a suitable embodiment of this invention, a formulation comprising a polynucleotide, a block copolymer, a cationic surfactant, an amorphous cryoprotectant or a crystalline bulking agent and a pH buffering agent are co-solubilized at a temperature below the cloud point of the block copolymer.
- In another suitable embodiment, the solution comprising a block copolymer, cationic surfactant, polynucleic acid and amorphous cryoprotectant or crystalline bulking agent also contains a physiologic buffer that maintains the solution pH within the range of about pH 4.0 to about pH 9.0. In a suitable embodiment, the pH of the co-solubilized mixture is about pH 5.0 to about pH 8.0, about pH 6.0 to about pH 8.0, or about pH 7.0 to about pH 7.5. For example, the pH of the co-solubilized mixture is about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, about pH 7.4 or about pH 7.5.
- pH buffering agents suitable for use in the invention include, but are not limited to, saline, PBS, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 3-(N-Morpholino)propanesulfonic acid (MOPS), 2-bis(2-Hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol (BIS-TRIS), potassium phosphate (KP), sodium phosphate (NaP), dibasic sodium phosphate (Na2HPO4), monobasic sodium phosphate (NaH2PO4), monobasic sodium potassium phosphate (NaKHPO4), magnesium phosphate (Mg3(PO4)2—4H2O), potassium acetate (CH3COOK), D(+)-α-sodium glycerophosphate (HOCH2CH(OH)CH2OPO3Na2) and other physiologic buffers known to those skilled in the art. Additional pH buffering agents for use in the invention include, a salt M-X dissolved in aqueous solution, association, or dissociation products thereof, where M is an alkali metal (e.g., Li+, Na+, K+, Rb+), suitably sodium or potassium, and where X is an anion selected from the group consisting of phosphate, acetate, bicarbonate, sulfate, pyruvate, and an organic monophosphate ester, preferably glucose 6-phosphate or DL-a-glycerol phosphate, and other physiologic buffers known to those skilled in the art. In a suitable embodiment of the invention, the pH buffering agent is selected from the group consisting of sodium phosphate, potassium phosphate, dibasic sodium phosphate (Na2HPO4), monobasic sodium phosphate (NaH2PO4), monobasic sodium potassium phosphate (NaKHPO4), magnesium phosphate (Mg3(PO4)2—4H2O), potassium acetate (CH3COOK), and D(+)-α-sodium glycerophosphate (HOCH2CH(OH)CH2OPO3Na2).
- In a suitable embodiment of the invention, the concentration of the pH buffering agent is from about 5 mM to about 25 mM. Suitably, a formulation of the present invention may have a final pH buffering agent concentration of about 7 mM to about 20 mM, or about 8 mM to about 15 mM, or about 9 mM to about 12 mM. For example, a formulation of the present invention may have a final pH buffering agent concentration of about 9 mM, about 10 mM, about 11 mM, or about 12 mM. In another suitable embodiment, the concentration of the pH buffering agent is about 10 mM.
- In another suitable embodiment of the invention, the concentration of the pH buffering agent selected from sodium phosphate, potassium phosphate, Na2HPO4, NaH2PO4, NaKHPO4, Mg3(PO4)2—4H2O, and HOCH2CH(OH)CH2OPO3Na2 is from about 5 mM to about 25 mM. Suitably, a formulation of the present invention may have a final concentration of pH buffering agent selected from sodium phosphate, potassium phosphate, Na2HPO4, NaH2PO4, NaKHPO4, Mg3(PO4)2—4H2O, and HOCH2CH(OH)CH2OPO3Na2 of about 7 mM to about 20 mM, about 8 mM to about 15 mM, or about 9 mM to about 12 mM. For example, a formulation of the present invention may have a final concentration of pH buffering agent selected from sodium phosphate, potassium phosphate, Na2HPO4, NaH2PO4, NaKHPO4, Mg3(PO4)2—4H2O, and HOCH2CH(OH)CH2OPO3Na2 of about 9 mM, about 10 mM, about 11 mM, or about 12 mM. In another suitable embodiment, the concentration of pH buffering agent selected from sodium phosphate, potassium phosphate, Na2HPO4, NaH2PO4, NaKHPO4, Mg3(PO4)2—4H2O, and HOCH2CH(OH)CH2OPO3Na2 is about 10 mM. In an alternative embodiment, the concentration of sodium phosphate is about 10 mM.
- In one suitable embodiment of the invention, a formulation comprising a polynucleic acid, block copolymer, cationic surfactant, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then lyophilized.
- In another suitable embodiment of the invention, a formulation comprising a polynucleic acid, a block copolymer, cationic surfactant, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then lyophilized.
- In another alternative embodiment, a formulation comprising a polynucleic acid, a block copolymer, cationic surfactant, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to lyophilization.
- In another suitable embodiment, a formulation comprising a polynucleic acid, a block copolymer, cationic surfactant, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to lyophilization.
- The cold filtration step must take place at a temperature below the cloud point of the block copolymer comprised in the formulation. The cold filtration step is suitably performed at a temperature between about −2° C. to about 8° C. For example, the cold filtration step can be performed at about −2° C., at about −1° C., at about 0° C., at about 1° C., at about 2° C., at about 3° C., at about 4° C., at about 5° C., at about 6° C., at about 7° C. or at about 8° C.
- The filtration of the cold solution (from about −2° C. to about 8° C.) of polynucleotide, block copolymer, and cationic surfactant provides a cost-effective and time-efficient method by which to sterilize the solution. This filtration step eliminates the need to pre-sterilize the polynucleotide, block copolymer and cationic surfactant prior to mixing. By passing the mixture through a sterile filter with a defined pore size smaller than bacterial pathogens, the solution is sterilized. The pore size of the filters utilized in the cold filtration step in the present invention are suitably from about 0.01 microns to about 2 microns. Alternatively, the pore size of the filters utilized in the cold filtration step in the present invention is about 0.05 microns to about 0.25 microns. For example, pore size of the filters for the cold filtration step can be about 0.05 microns, about 0.08 microns, about 0.1 microns, about 0.15 microns, about 0.16 microns, about 0.17 microns, about 0.18 microns, about 0.19 microns, about 0.2 microns, about 0.21 microns, about 0.22 microns, about 0.23 microns, about 0.24 microns, or about 0.25 microns.
- In an alternative embodiment of the invention, a formulation comprising a polynucleic acid, block copolymer, cationic surfactant, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In a suitable embodiment of the invention, a formulation comprising a polynucleic acid, block copolymer, cationic surfactant, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In another suitable embodiment, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- In another suitable embodiment, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- In another alternative embodiment, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then sterilized via cold filtering prior to lyophilization.
- In another suitable embodiment, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then sterilized via cold filtering prior to lyophilization.
- In another embodiment of the invention, a formulation comprises a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In another suitable embodiment of the invention, a formulation comprises a polynucleic acid, the block copolymer CRL-1005, the cationic surfactant BAK, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids:Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- In another suitable embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- In yet another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- In yet another suitable embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DhxRIE-OBz and Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- In yet another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In yet another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, a cationic surfactant selected from the following group of cationic lipids: Bn-DHxRIE, DHxRIE-OAc, DHxRIE-OBz and Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- In another suitable embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then lyophilized.
- In yet another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- In yet another suitable embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This mixture is then sterilized via cold filtering prior to freeze-drying.
- In yet another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, and an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- In yet another embodiment of the invention, a formulation comprising a polynucleic acid, the block copolymer CRL-1005, the cationic lipid Pr-DOctRIE-OAc, an amorphous cryoprotectant or crystalline bulking agent, such as 10% (w/v) sucrose, and a suitable pH buffering agent, such as 10 mM sodium phosphate, are co-solubilized at a temperature below the cloud point of the block copolymer. This solution is then cycled through its cloud point temperature several times, prior to being sterilized via cold filtering and subsequent freeze-drying.
- These example and equivalents thereof will become more apparent to those skilled in the art in light of the present disclosure and the accompanying claims. It should be understood, however, that the examples are designed for the purpose of illustration only and not limiting of the scope of the invention in any way. All patents and publications cited herein are fully incorporated by reference herein in their entirety.
- Aim: Prepare a DNA/poloxamer/BAK formulation (5 mg/ml DNA, 7.5 mg/mL CRL-1005, 0.3 mM BAK) in 10% sucrose, 10 mM sodium phosphate vehicle and lyophilize the formulation and determine the effect on particle size of the process.
- Apparatus: A 15 ml round bottom flask, with a ⅜″× 3/16″ egg-shaped magnetic stirrer bar (Bel-art products) and a coming stirrer/hotplate and an ice bath.
- Method: The required volume of DNA (6.1 mg/mL DNA, VR 4700, in 10% sucrose, 10 mM Sodium phosphate), was placed into the 15 mL round bottom flask and the solution stirred with a magnetic stirrer bar, in an ice bath on top of a Corning stirrer/hotplate (speed 4, hotplate off) for 10 minutes. The CRL-1005 was then added using a positive displacement pipette and the solution stirred for a further 30 minutes on ice. The required volume of BAK solution to give a final concentration of 0.3 mM was then added drop wise, slowly, to the stirring solution over 1 minute using a iml pipette. The solution at this point was clear since it was below the cloud point of the poloxamer and was stirred on ice for 30 minutes. The ice bath was then removed and the solution stirred at ambient temperature for 15 minutes to produce a cloudy solution as the poloxamer passed through the cloud point.
- The flask was then placed back into the ice bath and stirred for a further 15 minutes to produce a clear solution as the mixture cooled below the cloud point of the CRL-1005. The ice bath was again removed and the solution stirred for a further 15 minutes. Stirring for 15 minutes above and below the cloud point (total of 30 minutes), was defined as one thermal cycle. The mixture was cycled two more times. The solution was then diluted 1:2 with PBS and a 20 μL aliquot of the solution was then removed, diluted in 2 mL of filtered (0.2 μm) PBS and the particle size determined using a Malvern 3000 HS Zetasizer.
- The formulation was then filtered sterilized. A 50 mL Steriflip filtration system was placed in an ice bucket, with a vacuum line attached and left for 1 hour to allow the device to equilibrate to the temperature of the ice. The poloxamer formulation was then filtered under vacuum, below the cloud point and then allowed to warm above the cloud point. A 20 μL aliquot of the solution was then removed, diluted in 2 mL of filtered (0.2 μm) PBS and the particle size determined.
- Three 5 mL borosilicate vials (Wheaton) were then filled with 1 mL each of the formulation and the vials placed in a computer controlled Virtis Advantage freeze dryer. Initially the vials were cooled below −40° C. for at least two hours and then the condenser was cooled to below −40° C. and the vacuum reduced to below 300 mTorr. The first step in primary drying was to hold the vials at −40° C. for one hour, under a vacuum of 120 mTorr. Then the temperature was raised to 20° C. over eight hours and the vacuum maintained at 120 mTorr. After eight hours the temperature and vacuum were maintained for a further one-hour. The secondary drying step involved raising the temperature to 30° C. over 30 minutes and holding this temperature for a further two hours, while maintaining a vacuum of 120 mTorr. Finally the temperature was reduced to 20° C. over 30 minutes; the vials were sealed with grey butyl rubber stoppers (WestDireet) under vacuum and the samples removed for analysis.
- A similar procedure was used to prepare microparticles for lyophilization in PBS. The formulation contained final concentrations of 5 mg/ml DNA, 7.5 mg/mL CRL-1005, 0.3 mM BAK. The lyophilized particles in PBS were compared to the lyophilized particles in the 10% sucrose, 10 mM Sodium phosphate solution. Z average mean particle size and polydispersity were measured using a Malvern 3000 HS Zetasizer for both type of particles before and after lyophilization and the result are shown in Table 1.
-
TABLE 1 Z average Vehicle mean (nm) Polydispersity Before PBS 247.2 0.04 Lyophilization After PBS 268.8 0.59 Lyophilization Before 10% Sucrose 223.9 0.07 Lyophilization 10 mM NaP After 10% o Sucrose 205.4 0.10 Lyophilization 10 mM NaP - One of the lyophilized samples as prepared in the 10% sucrose, 10 mM Sodium phosphate solution as in Example 1 was reconstituted with 960 μl of sterile water for injection and gently mixed by hand and left on the bench top for 15 minutes. A 20 μl aliquot of this solution was then removed at 15, 60, 120, 240, 360 minute intervals, diluted in 2 ml of filtered (0.2 μm) 10% sucrose, 10 mM Sodium phosphate. The Z average mean and polydispersity of the particles in these aliquots were measured using a Malvern 3000 HS Zetasizer as above (
FIGS. 1A and IB). - Sterile formulations containing DNA, CRL-1005 and other poloxamers with cationic ionic lipids, including but not limited to, benzalkonium chloride in 8.5% sucrose can be prepared as described herein. The mixture is then lyophilized, and when reconstituted, these formulations may be used in immunogenicity studies. The T-cell responses of animals injected with the formulations described above can be measured by IFN-γ ELISpot assay and antigen-specific antibodies can be measured by ELISA. From the data, biologically active formulations with advantageous physical or pharmaceutical properties and/or formulations with enhanced biological activity can then be identified.
- Immunogenicity studies can be conducted using the experimental protocol as described below. Groups of nine, six- to eight-week old BALB/c mice (Harlan-Sprague-Dawley) will receive bilateral (50 μL/leg) intramuscular (rectus femoris) injections of naked plasmid DNA or formulated plasmid DNA. The plasmid (VR4700) to be injected in all mice encodes the influenza nucleoprotein (NP). All mice will be boosted on (approximately) days 21 and 49. Sera will be collected from NP-vaccinated mice after the third (˜ day 60) vaccination, and NP-specific antibody responses will be measured by ELISA. Two weeks after the last immunization, splenocytes will be harvested from three mice/group/day for three sequential days, and antigen specific T-cell responses will be measured by IFN-γ ELISpot assay.
- The NP-specific antibodies produced in response to DNA vaccination will be evaluated by ELISA. Briefly, 96 well Costar hi-binding ½ well ELISA plates are coated with 2 μg/mL of recombinant NP protein (Imgenex, San Diego, Calif.) and blocked with 10% fetal bovine serum (FBS) in PBS. Wells are incubated with serial dilutions of each immune serum, and bound anti-NP antibody is detected by the sequential addition of alkaline phosphatase-labeled goat anti-mouse IgG-Fcy and the colorimetric substrate, p-nitrophenylphosphate. Conversion of the substrate is quantified at 405 nm.
- The end-point dilution titer is defined as the reciprocal dilution at which the optical density at 405 run is greater than twice that measured in wells containing assay buffer alone (i.e., the background value). An average absorbance of eight wells containing assay buffer is used to establish the background value. Wells incubated with a pool of sera from NP DNA-vaccinated mice serve as a positive control.
- T-cell responses to the DNA vaccines will be determined by quantifying the number of splenocytes secreting IFN-γ in response to antigen-specific stimulation as measured by IFN-γ ELISpot assay. Splenocyte cultures will be grown in RPMI-1640 medium containing 25 mM HEPES buffer and L-glutamine and supplemented with 10% (v/v) FBS, 55 μM β-mercaptoethanol, 100 U/mL of penicillin G sodium salt, and 100 μg/mL of streptomycin sulfate. ImmunoSpot plates (Cellular Technology Limited, Cleveland, Ohio) are coated with rat anti-mouse IFN-γ monoclonal antibody (BD Biosciences, San Diego, Calif.), and blocked with RPMI-1640 medium. Splenocyte suspensions can be produced from individual vaccinated mice and seeded in ELISpot plates at 1×106, 3×105, or 1×105 cells/well in RPMI medium containing 1 μg/mL of the appropriate MHC class I-restricted peptide (M84, 297AYAGLFTPL305, Imgenex, San Diego, Calif.; NP, 147TYQRTRALV 155, Sigma/Genosys, The Woods, Tex.) or 20 μg/mL of protein antigen with (CD8+ T cell ELISpot assay) or without (CD4+ T cell ELISpot assay) 1 U/mL of recombinant murine IL-2 (Roche, Indianapolis, Ind.). Control wells contain 1×106 splenocytes incubated in medium with or without IL-2 only (no antigen). After a 20-hour incubation at 37° C., captured IFN-γ is detected by the sequential addition of biotin-labeled rat anti-mouse IFN-γ monoclonal antibody and avidin-horseradish peroxidase. Spots produced by the conversion of the colorimetric substrate, 3-amino-9-ethylcarbazole (AEC), are quantified by an ImmunoSpot reader (Cellular Technology Limited, Cleveland, Ohio).
Claims (9)
1. A method of preparing a lyophilized composition comprising:
(a) mixing
(i) a polyoxyethylene (POE) and polyoxypropylene (POP) block copolymer;
(ii) a polynucleotide;
(iii) a cationic surfactant; and
(iv) an amorphous cryoprotectant or a crystalline bulking agent; at a temperature below the cloud point of said block copolymer to form a mixture; and
(b) lyophilizing the mixture.
2. The method of claim 1 , further comprising a cold filtration step.
3. The method of claim 1 , wherein said mixture additionally comprises a pH stabilizing physiologic buffer.
4. A product produced by the process of claim 1 .
5. A stable, mono-dispersed product produced by reconstituting the product of claim 4 with an aqueous solution.
6. A product produced by the process of claim 2 .
7. A stable, mono-dispersed product produced by reconstituting the product of claim 6 with an aqueous solution.
8. A product produced by the process of claim 3 .
9. A stable, mono-dispersed product produced by reconstituting the product of claim 8 with an aqueous solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/407,653 US20090181919A1 (en) | 2002-12-23 | 2009-03-19 | Method for Freeze-Drying Nucleic Acid/Block Copolymer/Cationic Surfactant Complexes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43527302P | 2002-12-23 | 2002-12-23 | |
US10/725,009 US7521187B2 (en) | 2002-12-23 | 2003-12-02 | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US12/407,653 US20090181919A1 (en) | 2002-12-23 | 2009-03-19 | Method for Freeze-Drying Nucleic Acid/Block Copolymer/Cationic Surfactant Complexes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/725,009 Continuation US7521187B2 (en) | 2002-12-23 | 2003-12-02 | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090181919A1 true US20090181919A1 (en) | 2009-07-16 |
Family
ID=32713039
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/725,009 Expired - Fee Related US7521187B2 (en) | 2002-12-23 | 2003-12-02 | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US12/407,653 Abandoned US20090181919A1 (en) | 2002-12-23 | 2009-03-19 | Method for Freeze-Drying Nucleic Acid/Block Copolymer/Cationic Surfactant Complexes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/725,009 Expired - Fee Related US7521187B2 (en) | 2002-12-23 | 2003-12-02 | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
Country Status (6)
Country | Link |
---|---|
US (2) | US7521187B2 (en) |
EP (1) | EP1578193A4 (en) |
JP (1) | JP4917263B2 (en) |
AU (1) | AU2003293195A1 (en) |
CA (1) | CA2508279A1 (en) |
WO (1) | WO2004060059A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110064755A1 (en) * | 2004-12-03 | 2011-03-17 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
US11547764B2 (en) | 2011-06-08 | 2023-01-10 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11951181B2 (en) | 2023-04-03 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
JP4800485B2 (en) * | 1999-03-26 | 2011-10-26 | バイカル インコーポレイテッド | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
WO2001080897A2 (en) * | 2000-04-21 | 2001-11-01 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
EP1575505A4 (en) * | 2002-09-10 | 2007-01-24 | Vical Inc | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
EP1581201A4 (en) * | 2002-12-23 | 2011-03-30 | Vical Inc | Method for producing sterile polynucleotide based medicaments |
EP1578193A4 (en) * | 2002-12-23 | 2011-06-15 | Vical Inc | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
EP1766094A4 (en) | 2004-05-18 | 2009-11-25 | Vical Inc | Influenza virus vaccine composition and method of use |
AU2006270221B2 (en) | 2005-07-15 | 2012-01-19 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
KR100777249B1 (en) * | 2006-02-14 | 2007-11-28 | (주)바이오니아 | Dried Oligonucleotide Composition and Method of Producing the Same |
WO2007127363A2 (en) | 2006-04-26 | 2007-11-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
PL2034951T3 (en) | 2006-06-22 | 2013-06-28 | Biocompatibles Uk Ltd | Rehydratable pharmaceutical product |
EP2081694B1 (en) | 2006-10-23 | 2020-05-13 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
JP5603598B2 (en) | 2007-01-08 | 2014-10-08 | ミセル テクノロジーズ、インコーポレイテッド | Stent with biodegradable layer |
EP2170418B1 (en) | 2007-05-25 | 2016-03-16 | Micell Technologies, Inc. | Polymer films for medical device coating |
US20090258932A1 (en) * | 2008-04-09 | 2009-10-15 | Viromed Co., Ltd. | Lyophilized DNA Formulations for Enhanced Expression of Plasmid DNA |
SG192523A1 (en) | 2008-04-17 | 2013-08-30 | Micell Technologies Inc | Stents having bioabsorbable layers |
EP2309991B1 (en) | 2008-06-16 | 2019-03-06 | Pfizer Inc | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
KR101706178B1 (en) | 2008-06-16 | 2017-02-15 | 화이자 인코포레이티드 | Drug loaded polymeric nanoparticles and methods of making and using same |
CN102159257B (en) | 2008-07-17 | 2015-11-25 | 米歇尔技术公司 | Drug delivery medical device |
KR20100023538A (en) * | 2008-08-22 | 2010-03-04 | 삼성전자주식회사 | Manufacturing method of solid state reagent and microfluidic device accommodating the reagebt therein |
EA201100765A1 (en) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Long-term circulation nanoparticles |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
CA2757276C (en) | 2009-04-01 | 2017-06-06 | Micell Technologies, Inc. | Coated stents |
CA2759015C (en) | 2009-04-17 | 2017-06-20 | James B. Mcclain | Stents having controlled elution |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Drug delivery medical device |
JP5891175B2 (en) | 2009-12-11 | 2016-03-22 | バインド セラピューティックス インコーポレイテッド | Stable formulation against lyophilization of therapeutic particles |
EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
JP4653242B1 (en) * | 2010-02-12 | 2011-03-16 | ナノキャリア株式会社 | Particulate pharmaceutical composition |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
WO2012009684A2 (en) | 2010-07-16 | 2012-01-19 | Micell Technologies, Inc. | Drug delivery medical device |
CA2823355C (en) * | 2010-12-30 | 2017-08-22 | Micell Technologies, Inc. | Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
CA2885193C (en) | 2012-09-17 | 2021-04-27 | Bind Therapeutics, Inc. | Process for preparing therapeutic nanoparticles |
WO2014165264A1 (en) | 2013-03-12 | 2014-10-09 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
EP2996629B1 (en) | 2013-05-15 | 2021-09-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
KR20160011668A (en) * | 2013-06-24 | 2016-02-01 | 에프. 호프만-라 로슈 아게 | Stable intravenous formulation |
CA2926607C (en) | 2013-10-22 | 2018-10-23 | Viromed Co., Ltd. | Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor |
PL3116547T3 (en) | 2014-03-14 | 2019-11-29 | Pfizer | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
KR102175069B1 (en) * | 2017-11-10 | 2020-11-05 | 주식회사 삼양바이오팜 | Composition and process for freeze-drying of lipid nanoparticles for delivering an anionic drug |
EP3823677A4 (en) | 2018-07-19 | 2022-06-01 | Helixmith Co., Ltd. | Lyophilized pharmaceutical compositions for naked dna gene therapy |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5567859A (en) * | 1991-03-19 | 1996-10-22 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
US5679354A (en) * | 1988-09-30 | 1997-10-21 | Morein; Bror | Matrix with immunomodulating activity |
US5691387A (en) * | 1991-03-19 | 1997-11-25 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolmers with improved biological activity |
US5696298A (en) * | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
US5817334A (en) * | 1988-10-05 | 1998-10-06 | Nexstar Pharmaceuticals, Inc. | Method of making liposomes with improved stability during drying |
US5824322A (en) * | 1995-08-21 | 1998-10-20 | Cytrx Corporation | Compositions and methods for growth promotion |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
US5994317A (en) * | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US6086899A (en) * | 1994-08-09 | 2000-07-11 | Cytrx Corporation | Vaccine adjuvant and vaccine |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6251599B1 (en) * | 1998-11-06 | 2001-06-26 | Selective Genetics, Inc. | Stabilized nucleic acid compositions and methods of preparation and use thereof |
US20020019358A1 (en) * | 2000-04-21 | 2002-02-14 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
US6482518B1 (en) * | 1998-07-30 | 2002-11-19 | Point Biomedical Corporation | Excipient for the lyophilization of aqueous suspensions of microparticles |
US20030032615A1 (en) * | 1989-03-21 | 2003-02-13 | Vical Incorporated | Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response |
US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
US20030186913A1 (en) * | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6670332B1 (en) * | 1995-11-30 | 2003-12-30 | Vical Incorporated | Complex cationic lipids having quarternary nitrogens therein |
US20040157789A1 (en) * | 2002-12-23 | 2004-08-12 | Vical Incorporated. | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US20040162256A1 (en) * | 2002-12-23 | 2004-08-19 | Vical Incorporated. | Method for producing sterile polynucleotide based medicaments |
US20040209241A1 (en) * | 2002-12-23 | 2004-10-21 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US6933286B2 (en) * | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US20060027670A1 (en) * | 2004-08-04 | 2006-02-09 | Amichai Shdaimah | Humidity-controlled chamber for a thermogravimetric instrument |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US20070105193A1 (en) * | 2003-05-16 | 2007-05-10 | Vical Incorporated | Severe acute respiratory syndrome DNA vaccine compositions and methods of use |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
US20070286869A1 (en) * | 2004-05-18 | 2007-12-13 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US19358A (en) * | 1858-02-16 | Eire box ahd grate | ||
US32615A (en) * | 1861-06-25 | Washing-machine | ||
US186913A (en) * | 1877-01-30 | Improvement in silt-basins | ||
US203863A (en) * | 1878-05-21 | william l | ||
US171572A (en) * | 1875-12-28 | Improvement in mechanical movements | ||
US209241A (en) * | 1878-10-22 | Improvement in quadruplex-telegraph repeaters | ||
US36665A (en) * | 1862-10-14 | Improvement in pumps | ||
US191082A (en) * | 1877-05-22 | Improvement in the manufacture of gas | ||
EP0772687A2 (en) | 1994-07-29 | 1997-05-14 | Pioneer Hi-Bred International, Inc. | Transgenic cereal plants |
US6353055B1 (en) * | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
EP0833667A4 (en) * | 1995-06-07 | 2001-11-21 | Univ California | Stabilization of polynucleotide complexes |
DE69732029T2 (en) * | 1996-04-26 | 2006-02-23 | Merck & Co., Inc. | DNA-Containing VACCINES |
US5935936A (en) * | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
CA2306733A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
ATE294594T1 (en) * | 1998-03-13 | 2005-05-15 | Wyeth Corp | POLYNUCLEOTIDE COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF |
DE69902203T2 (en) | 1998-04-23 | 2003-02-20 | Fuji Photo Film Bv | Coated backing paper for photographic prints |
EP1230338B1 (en) * | 1999-11-19 | 2006-03-08 | Zycos Inc. | Continuous-flow method for preparing microparticles |
BR0108959A (en) | 2000-03-03 | 2003-10-14 | Valentis Inc | Improved poloxamer or poloxamine compositions for nucleic acid delivery |
AU2001270147A1 (en) * | 2000-06-23 | 2002-01-08 | Merck & Co., Inc. | Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
-
2003
- 2003-12-02 EP EP03790186A patent/EP1578193A4/en not_active Withdrawn
- 2003-12-02 AU AU2003293195A patent/AU2003293195A1/en not_active Abandoned
- 2003-12-02 WO PCT/US2003/038116 patent/WO2004060059A2/en active Application Filing
- 2003-12-02 CA CA002508279A patent/CA2508279A1/en not_active Abandoned
- 2003-12-02 US US10/725,009 patent/US7521187B2/en not_active Expired - Fee Related
- 2003-12-02 JP JP2004565150A patent/JP4917263B2/en not_active Expired - Fee Related
-
2009
- 2009-03-19 US US12/407,653 patent/US20090181919A1/en not_active Abandoned
Patent Citations (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
US5679354A (en) * | 1988-09-30 | 1997-10-21 | Morein; Bror | Matrix with immunomodulating activity |
US5817334A (en) * | 1988-10-05 | 1998-10-06 | Nexstar Pharmaceuticals, Inc. | Method of making liposomes with improved stability during drying |
US7250404B2 (en) * | 1989-03-21 | 2007-07-31 | Vical Incorporated | Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response |
US6867195B1 (en) * | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US20030032615A1 (en) * | 1989-03-21 | 2003-02-13 | Vical Incorporated | Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US20030186913A1 (en) * | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US5459127A (en) * | 1990-04-19 | 1995-10-17 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US6933286B2 (en) * | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US5696298A (en) * | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5990241A (en) * | 1991-03-19 | 1999-11-23 | Cytrx, Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5691387A (en) * | 1991-03-19 | 1997-11-25 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolmers with improved biological activity |
USRE36665E (en) * | 1991-03-19 | 2000-04-18 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5567859A (en) * | 1991-03-19 | 1996-10-22 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
US6086899A (en) * | 1994-08-09 | 2000-07-11 | Cytrx Corporation | Vaccine adjuvant and vaccine |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
US6399588B1 (en) * | 1994-11-28 | 2002-06-04 | Vical Incorporated | Cancer treatment method utilizing plasmids suitable for IL-2 expression |
US6147055A (en) * | 1994-11-28 | 2000-11-14 | Vical Incorporated | Cancer treatment method utilizing plasmids suitable for IL-2 expression |
US20050065107A1 (en) * | 1994-11-28 | 2005-03-24 | Hobart Peter M. | Plasmids suitable for IL-2 expression |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US20030203863A1 (en) * | 1994-11-28 | 2003-10-30 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US5824322A (en) * | 1995-08-21 | 1998-10-20 | Cytrx Corporation | Compositions and methods for growth promotion |
US20040171572A1 (en) * | 1995-11-30 | 2004-09-02 | Wheeler Carl J. | Complex cationic lipids having quaternary nitrogens therein |
US6670332B1 (en) * | 1995-11-30 | 2003-12-30 | Vical Incorporated | Complex cationic lipids having quarternary nitrogens therein |
US5994317A (en) * | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US6482518B1 (en) * | 1998-07-30 | 2002-11-19 | Point Biomedical Corporation | Excipient for the lyophilization of aqueous suspensions of microparticles |
US6251599B1 (en) * | 1998-11-06 | 2001-06-26 | Selective Genetics, Inc. | Stabilized nucleic acid compositions and methods of preparation and use thereof |
US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US20080213306A1 (en) * | 1999-03-26 | 2008-09-04 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US20080145387A1 (en) * | 1999-03-26 | 2008-06-19 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US20030191082A1 (en) * | 1999-03-26 | 2003-10-09 | Wheeler Carl J. | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6875748B2 (en) * | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
US20020019358A1 (en) * | 2000-04-21 | 2002-02-14 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
US20080085870A1 (en) * | 2002-12-23 | 2008-04-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20040162256A1 (en) * | 2002-12-23 | 2004-08-19 | Vical Incorporated. | Method for producing sterile polynucleotide based medicaments |
US7381422B2 (en) * | 2002-12-23 | 2008-06-03 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
US20040209241A1 (en) * | 2002-12-23 | 2004-10-21 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US7410795B2 (en) * | 2002-12-23 | 2008-08-12 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20040157789A1 (en) * | 2002-12-23 | 2004-08-12 | Vical Incorporated. | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US7521187B2 (en) * | 2002-12-23 | 2009-04-21 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US20070105193A1 (en) * | 2003-05-16 | 2007-05-10 | Vical Incorporated | Severe acute respiratory syndrome DNA vaccine compositions and methods of use |
US20070286869A1 (en) * | 2004-05-18 | 2007-12-13 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US20080057080A1 (en) * | 2004-05-18 | 2008-03-06 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US20120045467A1 (en) * | 2004-05-18 | 2012-02-23 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US20060027670A1 (en) * | 2004-08-04 | 2006-02-09 | Amichai Shdaimah | Humidity-controlled chamber for a thermogravimetric instrument |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110064755A1 (en) * | 2004-12-03 | 2011-03-17 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
US11547764B2 (en) | 2011-06-08 | 2023-01-10 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11730825B2 (en) | 2011-06-08 | 2023-08-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951181B2 (en) | 2023-04-03 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951180B2 (en) | 2023-04-03 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11951179B2 (en) | 2023-04-03 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
Also Published As
Publication number | Publication date |
---|---|
WO2004060059A3 (en) | 2005-12-22 |
US20040157789A1 (en) | 2004-08-12 |
EP1578193A4 (en) | 2011-06-15 |
US7521187B2 (en) | 2009-04-21 |
JP4917263B2 (en) | 2012-04-18 |
CA2508279A1 (en) | 2004-07-22 |
WO2004060059A2 (en) | 2004-07-22 |
JP2006515855A (en) | 2006-06-08 |
AU2003293195A1 (en) | 2004-07-29 |
EP1578193A2 (en) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7521187B2 (en) | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes | |
US8435557B2 (en) | Method for producing sterile polynucleotide based medicaments | |
US6875748B2 (en) | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics | |
US20060134221A1 (en) | Methods for producing block copolymer/amphiphilic particles | |
JP5153532B2 (en) | Stable lyophilized pharmaceutical formulation of monoclonal or polyclonal antibody | |
US7091030B2 (en) | Composition for the preservation of viruses | |
US8277823B2 (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
EP1206189B1 (en) | Rotavirus vaccine formulations | |
Christensen et al. | Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying | |
CA2572985C (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
WO2002011540A1 (en) | Rotavirus vaccine formulations | |
Abla et al. | Freeze-drying: A flourishing strategy to fabricate stable pharmaceutical and biological products | |
EP2381959A1 (en) | Stable vaccine compositions and methods of use | |
US20100183675A1 (en) | Stable vaccine compositions and methods of use | |
EP2461679B1 (en) | Vaccine stabilizer | |
Mohammed Saeid | Physiochemical stability and mass spectrometric analysis of gemini surfactant-based lipoplexes | |
US20130259948A1 (en) | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles | |
Schmidt et al. | The interplay between trehalose and dextran as spray drying precursors for cationic liposomes Anitta Lutta1, 2, Matthias M. Knopp3, Matteo Tollemeto1, Gabriel K. Pedersen2, Signe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |